primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
162277368,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2021,Q1,Intentional product misuse,,2021,Q1,8,F,201902.0,20210301.0,20190423,20210309,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20210309.0,,MD,US,US,2021,Q1,Adult
162277368,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2021,Q1,Ligament sprain,,2021,Q1,8,F,201902.0,20210301.0,20190423,20210309,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20210309.0,,MD,US,US,2021,Q1,Adult
162277368,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2021,Q1,Osteonecrosis,,2021,Q1,8,F,201902.0,20210301.0,20190423,20210309,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20210309.0,,MD,US,US,2021,Q1,Adult
162277368,16227736,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, DAILY",,,,,,,,300.0,MG,TABLET,,2021,Q1,Sleep disorder,,2021,Q1,8,F,201902.0,20210301.0,20190423,20210309,EXP,,US-PFIZER INC-2016573618,PFIZER,,50.0,YR,,M,Y,95.0,KG,20210309.0,,MD,US,US,2021,Q1,Adult
162879192,16287919,80,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,80,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Chronic kidney disease,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,80,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Nephrogenic anaemia,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
162879192,16287919,80,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Renal failure,,2021,Q1,2,F,20090914.0,20210210.0,20190508,20210218,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210218.0,,,US,US,2021,Q1,Elderly
172204042,17220404,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Prostatitis,,2021,Q1,2,F,,20210225.0,20191231,20210307,EXP,,JP-JNJFOC-20191246322,JOHNSON AND JOHNSON,,64.0,YR,A,M,Y,,,20210308.0,,MD,JP,JP,2021,Q1,Adult
172834773,17283477,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 DF,,,Y,,,,,1.0,DF,TABLET,,2021,Q1,Hyperglycaemia,,2021,Q1,3,F,20190327.0,20210315.0,20200117,20210330,EXP,,PHJP2019JP012389,NOVARTIS,,37.0,YR,,F,Y,,,20210330.0,,CN,FR,JP,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Decreased appetite,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Glomerular filtration rate decreased,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Polydipsia,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Urinary tract infection,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Urine output increased,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
180566712,18056671,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,,,,,100.0,MG,TABLET,,2021,Q1,Weight decreased,,2021,Q1,2,F,,20210113.0,20200722,20210122,EXP,,CA-APOTEX-2020AP013970,APOTEX,,53.0,YR,,M,Y,,,20210122.0,,CN,CA,CA,2021,Q1,Adult
182176013,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,3,F,20200515.0,20210317.0,20200901,20210331,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210331.0,,HP,JP,JP,2021,Q1,Adult
182176013,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dyshidrotic eczema,,2021,Q1,3,F,20200515.0,20210317.0,20200901,20210331,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210331.0,,HP,JP,JP,2021,Q1,Adult
182176013,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Enteritis infectious,,2021,Q1,3,F,20200515.0,20210317.0,20200901,20210331,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210331.0,,HP,JP,JP,2021,Q1,Adult
182176013,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Erythema multiforme,,2021,Q1,3,F,20200515.0,20210317.0,20200901,20210331,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210331.0,,HP,JP,JP,2021,Q1,Adult
182176013,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Nasopharyngitis,,2021,Q1,3,F,20200515.0,20210317.0,20200901,20210331,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210331.0,,HP,JP,JP,2021,Q1,Adult
182275603,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2021,Q1,Acute kidney injury,,2021,Q1,3,F,,20201230.0,20200903,20210111,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,68.0,YR,,M,Y,,,20210111.0,,HP,US,US,2021,Q1,Elderly
182275603,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2021,Q1,Diarrhoea,,2021,Q1,3,F,,20201230.0,20200903,20210111,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,68.0,YR,,M,Y,,,20210111.0,,HP,US,US,2021,Q1,Elderly
182275603,18227560,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MILLIGRAM, QD",,,Y,U,,,,300.0,MG,,QD,2021,Q1,Nephrotic syndrome,,2021,Q1,3,F,,20201230.0,20200903,20210111,EXP,,US-MYLANLABS-2020M1076069,MYLAN,,68.0,YR,,M,Y,,,20210111.0,,HP,US,US,2021,Q1,Elderly
183763953,18376395,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,D,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Metabolic acidosis,,2021,Q1,3,F,20200927.0,20210113.0,20201013,20210128,EXP,,JP-JNJFOC-20201006952,JOHNSON AND JOHNSON,,69.0,YR,E,F,Y,,,20210128.0,,PH,JP,JP,2021,Q1,Elderly
185262864,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Abnormal loss of weight,,2021,Q1,4,F,20181117.0,20210112.0,20201120,20210121,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"KOYA D, HIRAI T, KITADA M, HAYASHI Y, MONNO I, TAKAGAKI Y, SHIMADA K, OGURA Y, FUJII M, KONISHI K, NAKAGAWA A. CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUMGLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION. J DIABETES INVESTIG. 2020?11:1359?1362.",58.0,YR,A,F,Y,,,20210121.0,,HP,JP,JP,2021,Q1,Adult
185262864,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dehydration,,2021,Q1,4,F,20181117.0,20210112.0,20201120,20210121,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"KOYA D, HIRAI T, KITADA M, HAYASHI Y, MONNO I, TAKAGAKI Y, SHIMADA K, OGURA Y, FUJII M, KONISHI K, NAKAGAWA A. CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUMGLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION. J DIABETES INVESTIG. 2020?11:1359?1362.",58.0,YR,A,F,Y,,,20210121.0,,HP,JP,JP,2021,Q1,Adult
185262864,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Ketoacidosis,,2021,Q1,4,F,20181117.0,20210112.0,20201120,20210121,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"KOYA D, HIRAI T, KITADA M, HAYASHI Y, MONNO I, TAKAGAKI Y, SHIMADA K, OGURA Y, FUJII M, KONISHI K, NAKAGAWA A. CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUMGLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION. J DIABETES INVESTIG. 2020?11:1359?1362.",58.0,YR,A,F,Y,,,20210121.0,,HP,JP,JP,2021,Q1,Adult
185262864,18526286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Superior mesenteric artery syndrome,,2021,Q1,4,F,20181117.0,20210112.0,20201120,20210121,EXP,,JP-JNJFOC-20201132246,JOHNSON AND JOHNSON,"KOYA D, HIRAI T, KITADA M, HAYASHI Y, MONNO I, TAKAGAKI Y, SHIMADA K, OGURA Y, FUJII M, KONISHI K, NAKAGAWA A. CASE REPORT OF SUPERIOR MESENTERIC ARTERY SYNDROME THAT DEVELOPED IN A LEAN TYPE 2 DIABETES PATIENT AND WAS ASSOCIATED WITH RAPID BODY WEIGHT LOSS AFTER SODIUMGLUCOSE COTRANSPORTER 2 INHIBITOR ADMINISTRATION. J DIABETES INVESTIG. 2020?11:1359?1362.",58.0,YR,A,F,Y,,,20210121.0,,HP,JP,JP,2021,Q1,Adult
185886842,18588684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",19700.0,MG,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Atheroembolism,,2021,Q1,2,F,20201014.0,20210201.0,20201207,20210209,EXP,,JP-JNJFOC-20201207649,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20210209.0,,PH,JP,JP,2021,Q1,Elderly
185886842,18588684,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",19700.0,MG,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Cerebral infarction,,2021,Q1,2,F,20201014.0,20210201.0,20201207,20210209,EXP,,JP-JNJFOC-20201207649,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20210209.0,,PH,JP,JP,2021,Q1,Elderly
186251745,18625174,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",70400.0,MG,,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Eczema,,2021,Q1,5,F,20201106.0,20210319.0,20201217,20210329,EXP,,JP-JNJFOC-20201225437,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210329.0,,MD,JP,JP,2021,Q1,Elderly
186416842,18641684,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,Y,,,,,100.0,MG,,,2021,Q1,Blood pressure decreased,,2021,Q1,2,F,20201120.0,20210115.0,20201221,20210127,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20210127.0,,MD,JP,JP,2021,Q1,Elderly
186416842,18641684,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,Y,,,,,100.0,MG,,,2021,Q1,Low cardiac output syndrome,,2021,Q1,2,F,20201120.0,20210115.0,20201221,20210127,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20210127.0,,MD,JP,JP,2021,Q1,Elderly
186416842,18641684,5,SS,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,100 MG,,,Y,,,,,100.0,MG,,,2021,Q1,Sepsis,,2021,Q1,2,F,20201120.0,20210115.0,20201221,20210127,EXP,,NVSJ2020JP013917,NOVARTIS,,65.0,YR,,M,Y,90.0,KG,20210127.0,,MD,JP,JP,2021,Q1,Elderly
187058801,18705880,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2021,Q1,Drug interaction,Drug interaction,2021,Q1,1,I,,20201227.0,20210106,20210106,EXP,,CA-ALLIED PHARMA-000017,ALLIED PHARMA,,76.0,YR,E,F,Y,,,20210106.0,,MD,CA,CA,2021,Q1,Elderly
187058801,18705880,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2021,Q1,Hepatocellular injury,Hepatocellular injury,2021,Q1,1,I,,20201227.0,20210106,20210106,EXP,,CA-ALLIED PHARMA-000017,ALLIED PHARMA,,76.0,YR,E,F,Y,,,20210106.0,,MD,CA,CA,2021,Q1,Elderly
187058801,18705880,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2021,Q1,Rhabdomyolysis,Rhabdomyolysis,2021,Q1,1,I,,20201227.0,20210106,20210106,EXP,,CA-ALLIED PHARMA-000017,ALLIED PHARMA,,76.0,YR,E,F,Y,,,20210106.0,,MD,CA,CA,2021,Q1,Elderly
187058801,18705880,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG DAILY,,,Y,,,,,100.0,MG,,,2021,Q1,Toxicity to various agents,Toxicity to various agents,2021,Q1,1,I,,20201227.0,20210106,20210106,EXP,,CA-ALLIED PHARMA-000017,ALLIED PHARMA,,76.0,YR,E,F,Y,,,20210106.0,,MD,CA,CA,2021,Q1,Elderly
187181661,18718166,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q1,Cerebrovascular accident,,2021,Q1,1,I,,20201230.0,20210108,20210108,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202012014510,ELI LILLY AND CO,,62.0,YR,,M,Y,64.0,KG,20210108.0,,CN,CN,CN,2021,Q1,Adult
187421911,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q1,Bladder cancer,,2021,Q1,1,I,20200916.0,20200624.0,20210114,20210114,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20210114.0,,CN,IE,IE,2021,Q1,Elderly
187421911,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q1,Device infusion issue,,2021,Q1,1,I,20200916.0,20200624.0,20210114,20210114,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20210114.0,,CN,IE,IE,2021,Q1,Elderly
187421911,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q1,Expired product administered,,2021,Q1,1,I,20200916.0,20200624.0,20210114,20210114,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20210114.0,,CN,IE,IE,2021,Q1,Elderly
187421911,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q1,Inappropriate schedule of product administration,,2021,Q1,1,I,20200916.0,20200624.0,20210114,20210114,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20210114.0,,CN,IE,IE,2021,Q1,Elderly
187421911,18742191,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q1,Urinary tract infection,,2021,Q1,1,I,20200916.0,20200624.0,20210114,20210114,EXP,,IE-SHIRE-IE202020753,TAKEDA,,84.0,YR,,M,Y,,,20210114.0,,CN,IE,IE,2021,Q1,Elderly
187426821,18742682,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,CANAGLIFLOZIN 100 AND METFORMIN 850 MG,,,Y,,,,204353.0,,,TABLET,,2021,Q1,Euglycaemic diabetic ketoacidosis,,2021,Q1,1,I,,20210108.0,20210115,20210115,EXP,,BE-JNJFOC-20210113975,JOHNSON AND JOHNSON,"MENGHOUM N, ORIOT P, HERMANS MP, MARIAGE JL,  [DIABETIC EUGLYCEMIC KETOSIS OR KETOACIDOSIS IN INDIVIDUALS WITH TYPE 2 DIABETES TREATED BY SGLT2 INHIBITORS: A SERIES OF BELGIAN CLINICAL CASES]. REVUE DE MEDECINE INTERNE 2020 41 226?231",74.0,YR,E,M,Y,,,20210115.0,,HP,BE,BE,2021,Q1,Elderly
187426821,18742682,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,CANAGLIFLOZIN 100 AND METFORMIN 850 MG,,,Y,,,,204353.0,,,TABLET,,2021,Q1,Streptococcal sepsis,,2021,Q1,1,I,,20210108.0,20210115,20210115,EXP,,BE-JNJFOC-20210113975,JOHNSON AND JOHNSON,"MENGHOUM N, ORIOT P, HERMANS MP, MARIAGE JL,  [DIABETIC EUGLYCEMIC KETOSIS OR KETOACIDOSIS IN INDIVIDUALS WITH TYPE 2 DIABETES TREATED BY SGLT2 INHIBITORS: A SERIES OF BELGIAN CLINICAL CASES]. REVUE DE MEDECINE INTERNE 2020 41 226?231",74.0,YR,E,M,Y,,,20210115.0,,HP,BE,BE,2021,Q1,Elderly
187599941,18759994,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,,,,,,100.0,MG,,,2021,Q1,Cardiac failure,,2021,Q1,1,I,2021.0,20210112.0,20210120,20210120,PER,,JP-AMGEN-JPNSP2021008289,AMGEN,,52.0,YR,A,M,Y,100.0,KG,20210120.0,,MD,JP,JP,2021,Q1,Adult
187599941,18759994,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,,,,,,100.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2021.0,20210112.0,20210120,20210120,PER,,JP-AMGEN-JPNSP2021008289,AMGEN,,52.0,YR,A,M,Y,100.0,KG,20210120.0,,MD,JP,JP,2021,Q1,Adult
187599941,18759994,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,,,,,,100.0,MG,,,2021,Q1,Cardiac failure,,2021,Q1,1,I,2021.0,20210112.0,20210120,20210120,PER,,JP-AMGEN-JPNSP2021008289,AMGEN,,52.0,YR,A,M,Y,100.0,KG,20210120.0,,MD,JP,JP,2021,Q1,Adult
187599941,18759994,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MG,,,,,,,,100.0,MG,,,2021,Q1,Pneumonia,,2021,Q1,1,I,2021.0,20210112.0,20210120,20210120,PER,,JP-AMGEN-JPNSP2021008289,AMGEN,,52.0,YR,A,M,Y,100.0,KG,20210120.0,,MD,JP,JP,2021,Q1,Adult
187647591,18764759,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,426000.0,MG,Y,,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210107.0,20210118.0,20210120,20210120,EXP,GB-MHRA-MIDB-88E2B2F5-2F8E-493A-8E30-DD2D975CF928,GB-JNJFOC-20210131147,JOHNSON AND JOHNSON,,33.0,YR,A,F,Y,,,20210121.0,,PH,GB,GB,2021,Q1,Young Adult
187667961,18766796,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U," UNKNOWN,UNKNOWN",,204042.0,,,TABLET,,2021,Q1,Myocardial infarction,,2021,Q1,1,I,20210118.0,20210118.0,20210121,20210121,EXP,,US-JNJFOC-20210129856,JOHNSON AND JOHNSON,,61.0,YR,A,M,Y,,,20210121.0,,CN,US,US,2021,Q1,Adult
187712091,18771209,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,TAKE ONE DAILY 10/06/2019,172512.5,MG,U,U, UNKNOWN,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210105.0,20210119.0,20210122,20210122,EXP,GB-MHRA-TPP3304131C5993572YC1609866344296,GB-JNJFOC-20210131032,JOHNSON AND JOHNSON,,53.0,YR,A,F,Y,77.0,KG,20210122.0,,MD,GB,GB,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Albumin globulin ratio increased,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Chills,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Ejection fraction decreased,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Encephalopathy,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Fluid retention,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Hypernatraemia,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Illness,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Leukocytosis,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Lung infiltration,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pain,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pneumonia,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Productive cough,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Pyrexia,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Respiratory rate increased,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Right ventricular dilatation,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188079071,18807907,17,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Tachypnoea,,2021,Q1,1,I,20210125.0,,20210129,20210129,DIR,,,FDA-CTU,,63.0,YR,,M,N,115.0,KG,20210129.0,Y,HP,US,US,2021,Q1,Adult
188086621,18808662,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210118.0,20210129,20210129,EXP,,CA-MSNLABS-2021MSNLIT00024,MSN LABORATORIES,,76.0,YR,E,F,Y,,,20210129.0,,MD,CA,CA,2021,Q1,Elderly
188086621,18808662,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2021,Q1,Hepatocellular injury,,2021,Q1,1,I,,20210118.0,20210129,20210129,EXP,,CA-MSNLABS-2021MSNLIT00024,MSN LABORATORIES,,76.0,YR,E,F,Y,,,20210129.0,,MD,CA,CA,2021,Q1,Elderly
188086621,18808662,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,,20210118.0,20210129,20210129,EXP,,CA-MSNLABS-2021MSNLIT00024,MSN LABORATORIES,,76.0,YR,E,F,Y,,,20210129.0,,MD,CA,CA,2021,Q1,Elderly
188086621,18808662,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2021,Q1,Toxicity to various agents,,2021,Q1,1,I,,20210118.0,20210129,20210129,EXP,,CA-MSNLABS-2021MSNLIT00024,MSN LABORATORIES,,76.0,YR,E,F,Y,,,20210129.0,,MD,CA,CA,2021,Q1,Elderly
188278082,18827808,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Haemorrhage subcutaneous,,2021,Q1,2,F,,20210305.0,20210202,20210310,EXP,,JP-JNJFOC-20210146209,JOHNSON AND JOHNSON,,72.0,YR,E,M,Y,,,20210311.0,,PH,JP,JP,2021,Q1,Elderly
188325421,18832542,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Diabetic foot infection,,2021,Q1,1,I,,20210127.0,20210203,20210203,EXP,,CA-JNJFOC-20210148143,JOHNSON AND JOHNSON,,30.0,YR,A,M,Y,,,20210203.0,,PH,CA,CA,2021,Q1,Young Adult
188325421,18832542,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Localised infection,,2021,Q1,1,I,,20210127.0,20210203,20210203,EXP,,CA-JNJFOC-20210148143,JOHNSON AND JOHNSON,,30.0,YR,A,M,Y,,,20210203.0,,PH,CA,CA,2021,Q1,Young Adult
188366091,18836609,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",59300.0,MG,,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Nephrogenic anaemia,,2021,Q1,1,I,20180619.0,20210125.0,20210203,20210203,EXP,,JP-JNJFOC-20210203220,JOHNSON AND JOHNSON,,63.0,YR,A,M,Y,,,20210203.0,,MD,JP,JP,2021,Q1,Adult
188372041,18837204,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210123.0,20210129.0,20210203,20210203,EXP,GB-MHRA-EYC 00238937,GB-MYLANLABS-2021M1006579,MYLAN,,49.0,YR,,M,Y,,,20210203.0,,HP,GB,GB,2021,Q1,Adult
188372041,18837204,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Lethargy,,2021,Q1,1,I,20210123.0,20210129.0,20210203,20210203,EXP,GB-MHRA-EYC 00238937,GB-MYLANLABS-2021M1006579,MYLAN,,49.0,YR,,M,Y,,,20210203.0,,HP,GB,GB,2021,Q1,Adult
188372041,18837204,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Nausea,,2021,Q1,1,I,20210123.0,20210129.0,20210203,20210203,EXP,GB-MHRA-EYC 00238937,GB-MYLANLABS-2021M1006579,MYLAN,,49.0,YR,,M,Y,,,20210203.0,,HP,GB,GB,2021,Q1,Adult
188429526,18842952,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Benign prostatic hyperplasia,,2021,Q1,6,F,20210125.0,20210312.0,20210203,20210317,EXP,,US-ELI_LILLY_AND_COMPANY-US202101013046,ELI LILLY AND CO,,62.0,YR,,M,Y,115.0,KG,20210317.0,,HP,US,US,2021,Q1,Adult
188429526,18842952,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,COVID-19 pneumonia,,2021,Q1,6,F,20210125.0,20210312.0,20210203,20210317,EXP,,US-ELI_LILLY_AND_COMPANY-US202101013046,ELI LILLY AND CO,,62.0,YR,,M,Y,115.0,KG,20210317.0,,HP,US,US,2021,Q1,Adult
188429526,18842952,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,6,F,20210125.0,20210312.0,20210203,20210317,EXP,,US-ELI_LILLY_AND_COMPANY-US202101013046,ELI LILLY AND CO,,62.0,YR,,M,Y,115.0,KG,20210317.0,,HP,US,US,2021,Q1,Adult
188429526,18842952,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Encephalopathy,,2021,Q1,6,F,20210125.0,20210312.0,20210203,20210317,EXP,,US-ELI_LILLY_AND_COMPANY-US202101013046,ELI LILLY AND CO,,62.0,YR,,M,Y,115.0,KG,20210317.0,,HP,US,US,2021,Q1,Adult
188429526,18842952,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Hypoglycaemia,,2021,Q1,6,F,20210125.0,20210312.0,20210203,20210317,EXP,,US-ELI_LILLY_AND_COMPANY-US202101013046,ELI LILLY AND CO,,62.0,YR,,M,Y,115.0,KG,20210317.0,,HP,US,US,2021,Q1,Adult
188449441,18844944,5,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Oral,50/1000,,,,,,,,,,,,2021,Q1,Squamous cell carcinoma,,2021,Q1,1,I,20201222.0,20210129.0,20210204,20210204,EXP,,ES-GILEAD-2021-0515872,GILEAD,,70.0,YR,E,M,Y,,,20210204.0,,PH,ES,ES,2021,Q1,Elderly
188515521,18851552,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",24600.0,MG,,, UNK,,,50.0,MG,TABLET,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210123.0,20210129.0,20210205,20210205,EXP,GB-MHRA-ADR 24655019,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-000343,EMCURE,,49.0,YR,,M,Y,,,20210205.0,,HP,GB,GB,2021,Q1,Adult
188515521,18851552,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",24600.0,MG,,, UNK,,,50.0,MG,TABLET,,2021,Q1,Lethargy,,2021,Q1,1,I,20210123.0,20210129.0,20210205,20210205,EXP,GB-MHRA-ADR 24655019,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-000343,EMCURE,,49.0,YR,,M,Y,,,20210205.0,,HP,GB,GB,2021,Q1,Adult
188515521,18851552,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, BID",24600.0,MG,,, UNK,,,50.0,MG,TABLET,,2021,Q1,Nausea,,2021,Q1,1,I,20210123.0,20210129.0,20210205,20210205,EXP,GB-MHRA-ADR 24655019,GB-EMCURE PHARMACEUTICALS LTD-2021-EPL-000343,EMCURE,,49.0,YR,,M,Y,,,20210205.0,,HP,GB,GB,2021,Q1,Adult
188548231,18854823,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, TWO TIMES A DAY",24600.0,MG,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210123.0,20210129.0,20210206,20210206,EXP,,GB-AUROBINDO-AUR-APL-2021-004623,AUROBINDO,,49.0,YR,,M,Y,,,20210206.0,,HP,GB,GB,2021,Q1,Adult
188548231,18854823,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, TWO TIMES A DAY",24600.0,MG,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Lethargy,,2021,Q1,1,I,20210123.0,20210129.0,20210206,20210206,EXP,,GB-AUROBINDO-AUR-APL-2021-004623,AUROBINDO,,49.0,YR,,M,Y,,,20210206.0,,HP,GB,GB,2021,Q1,Adult
188548231,18854823,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,"50 MILLIGRAM, TWO TIMES A DAY",24600.0,MG,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Nausea,,2021,Q1,1,I,20210123.0,20210129.0,20210206,20210206,EXP,,GB-AUROBINDO-AUR-APL-2021-004623,AUROBINDO,,49.0,YR,,M,Y,,,20210206.0,,HP,GB,GB,2021,Q1,Adult
188607913,18860791,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Cataract,,2021,Q1,3,F,,20210209.0,20210208,20210305,EXP,,JP-JNJFOC-20210209435,JOHNSON AND JOHNSON,,83.0,YR,E,M,Y,,,20210305.0,,MD,JP,JP,2021,Q1,Elderly
188619841,18861984,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,,50.0,MG,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210123.0,20210201.0,20210209,20210209,EXP,GB-MHRA-EYC 00238937,GB-EMD SERONO-E2B_90082238,EMD SERONO INC,,49.0,YR,A,M,Y,,,20210209.0,,HP,GB,GB,2021,Q1,Adult
188619841,18861984,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,,50.0,MG,TABLET,QD,2021,Q1,Lethargy,,2021,Q1,1,I,20210123.0,20210201.0,20210209,20210209,EXP,GB-MHRA-EYC 00238937,GB-EMD SERONO-E2B_90082238,EMD SERONO INC,,49.0,YR,A,M,Y,,,20210209.0,,HP,GB,GB,2021,Q1,Adult
188619841,18861984,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,U,,,,50.0,MG,TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,20210123.0,20210201.0,20210209,20210209,EXP,GB-MHRA-EYC 00238937,GB-EMD SERONO-E2B_90082238,EMD SERONO INC,,49.0,YR,A,M,Y,,,20210209.0,,HP,GB,GB,2021,Q1,Adult
188683522,18868352,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",8900.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Fournier's gangrene,,2021,Q1,2,F,20200622.0,20210217.0,20210209,20210226,EXP,,JP-JNJFOC-20210214244,JOHNSON AND JOHNSON,,61.0,YR,A,M,Y,,,20210227.0,,PH,JP,JP,2021,Q1,Adult
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Abdominal pain,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Anal fistula,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Fournier's gangrene,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Nausea,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Prostatitis,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188782841,18878284,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Rectal abscess,,2021,Q1,1,I,,20200504.0,20210211,20210211,EXP,,CA-BAYER-2020-085910,BAYER,,72.0,YR,E,M,Y,,,20210211.0,,HP,NL,CA,2021,Q1,Elderly
188861801,18886180,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,20210123.0,20210129.0,20210212,20210212,EXP,GB-MHRA-EYC 00238937,GB-TEVA-2021-GB-1876494,TEVA,,49.0,YR,A,M,Y,,,20210212.0,,HP,GB,GB,2021,Q1,Adult
188861801,18886180,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Lethargy,,2021,Q1,1,I,20210123.0,20210129.0,20210212,20210212,EXP,GB-MHRA-EYC 00238937,GB-TEVA-2021-GB-1876494,TEVA,,49.0,YR,A,M,Y,,,20210212.0,,HP,GB,GB,2021,Q1,Adult
188861801,18886180,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,U,,,,50.0,MG,TABLET,BID,2021,Q1,Nausea,,2021,Q1,1,I,20210123.0,20210129.0,20210212,20210212,EXP,GB-MHRA-EYC 00238937,GB-TEVA-2021-GB-1876494,TEVA,,49.0,YR,A,M,Y,,,20210212.0,,HP,GB,GB,2021,Q1,Adult
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Arthralgia,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure diastolic abnormal,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure diastolic decreased,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure fluctuation,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Blood pressure increased,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Breast disorder,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Contusion,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Cystitis,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Drug ineffective,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Fall,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Fibromyalgia,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Finger deformity,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Heart rate increased,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Hypertension,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Hypotension,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Hypothyroidism,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Intentional product use issue,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Intercepted medication error,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Kidney infection,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Lower respiratory tract infection,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Nasopharyngitis,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Nodule,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Pain,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Rheumatoid arthritis,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Steroid diabetes,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Urinary tract infection,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Vascular stenosis,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188950021,18895002,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,1,I,,20210208.0,20210215,20210215,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013182,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210215.0,,HP,CA,CA,2021,Q1,Elderly
188959552,18895955,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Acidosis,,2021,Q1,2,F,,20210222.0,20210216,20210301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-083071",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20210301.0,,PH,JP,JP,2021,Q1,Elderly
188959552,18895955,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q1,Diabetes mellitus inadequate control,,2021,Q1,2,F,,20210222.0,20210216,20210301,EXP,,"JP-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2021-BI-083071",BOEHRINGER INGELHEIM,,77.0,YR,E,M,Y,,,20210301.0,,PH,JP,JP,2021,Q1,Elderly
188996541,18899654,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,,20201116.0,20210216,20210216,EXP,,IT-JNJFOC-20201134480,JOHNSON AND JOHNSON,"GAMBINO R, SABA F, CASSADER M, MUSSO G. DIABETIC KETOACIDOSIS WITH SGLT2 INHIBITORS. BRITISH MEDICAL JOURNAL. 2020?371:.",45.0,YR,A,F,Y,,,20210216.0,,HP,IT,IT,2021,Q1,Adult
189040731,18904073,8,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q1,Myocarditis,,2021,Q1,1,I,,20210210.0,20210217,20210217,EXP,,CA-CELGENEUS-CAN-20210203383,CELGENE,,61.0,YR,,M,Y,,,20210217.0,,HP,CA,CA,2021,Q1,Adult
189126821,18912682,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 MG 1X TGL,,,N,Y,,,204042.0,300.0,MG,TABLET,,2021,Q1,Fournier's gangrene,,2021,Q1,1,I,20210201.0,20210217.0,20210219,20210219,EXP,DE-BFARM-21001454,DE-JNJFOC-20210229324,JOHNSON AND JOHNSON,,56.0,YR,A,F,Y,102.0,KG,20210219.0,,PH,DE,DE,2021,Q1,Adult
189152831,18915283,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,UNKNOWN,,2021,Q1,Feeling abnormal,,2021,Q1,1,I,20210210.0,20210217.0,20210219,20210219,EXP,GB-MHRA-TPP34252749C4047751YC1612977588642,GB-JNJFOC-20210229774,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,108.0,KG,20210219.0,,HP,GB,GB,2021,Q1,Elderly
189152831,18915283,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,UNKNOWN,,2021,Q1,Malaise,,2021,Q1,1,I,20210210.0,20210217.0,20210219,20210219,EXP,GB-MHRA-TPP34252749C4047751YC1612977588642,GB-JNJFOC-20210229774,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,108.0,KG,20210219.0,,HP,GB,GB,2021,Q1,Elderly
189152831,18915283,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,2.0,DF,UNKNOWN,,2021,Q1,Paraesthesia,,2021,Q1,1,I,20210210.0,20210217.0,20210219,20210219,EXP,GB-MHRA-TPP34252749C4047751YC1612977588642,GB-JNJFOC-20210229774,JOHNSON AND JOHNSON,,69.0,YR,E,M,Y,108.0,KG,20210219.0,,HP,GB,GB,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Arthralgia,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Blood pressure diastolic abnormal,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Blood pressure diastolic decreased,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Blood pressure fluctuation,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Blood pressure increased,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Breast disorder,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Contusion,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Cystitis,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Drug ineffective,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Fall,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Fibromyalgia,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Finger deformity,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Heart rate increased,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Hypertension,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Hypotension,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Hypothyroidism,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Intentional product use issue,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Intercepted medication error,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Kidney infection,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Lower respiratory tract infection,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Nasopharyngitis,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Nodule,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Oxygen saturation decreased,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Pain,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Rheumatoid arthritis,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Steroid diabetes,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Urinary tract infection,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Vascular stenosis,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189236271,18923627,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q1,Weight decreased,,2021,Q1,1,I,,20210208.0,20210222,20210222,EXP,,CA-PFIZER INC-2021170745,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210222.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Drug level increased,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Gait disturbance,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Hepatocellular injury,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Laboratory test abnormal,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Rhabdomyolysis,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189259461,18925946,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, ONCE A DAY",,,U,U,,,,100.0,MG,,QD,2021,Q1,Toxicity to various agents,,2021,Q1,1,I,,20210212.0,20210222,20210222,EXP,,CA-AUROBINDO-AUR-APL-2021-007222,AUROBINDO,,76.0,YR,,F,Y,,,20210223.0,,HP,CA,CA,2021,Q1,Elderly
189741591,18974159,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Peripheral arterial occlusive disease,,2021,Q1,1,I,20200624.0,20200701.0,20210305,20210305,EXP,,JP-JNJFOC-20200714930,JOHNSON AND JOHNSON,,70.0,YR,E,M,Y,,,20210305.0,,MD,JP,JP,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Asthenia,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Bacteraemia,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Blister,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dry mouth,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Fungal infection,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Peripheral swelling,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Urticaria,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q1,Vomiting,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Asthenia,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Bacteraemia,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Blister,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Diabetic ketoacidosis,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Diarrhoea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Dizziness,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Dry mouth,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Dyspnoea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Fungal infection,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Loss of personal independence in daily activities,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Nausea,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Peripheral swelling,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Urticaria,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
189743931,18974393,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q1,Vomiting,,2021,Q1,1,I,,20210224.0,20210305,20210305,EXP,,CA-JNJFOC-20210247216,JOHNSON AND JOHNSON,,68.0,YR,E,F,Y,81.72,KG,20210305.0,,CN,CA,CA,2021,Q1,Elderly
190017741,19001774,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Asthma,,2021,Q1,1,I,,20210222.0,20210312,20210312,EXP,,CA-JNJFOC-20210316789,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210312.0,,MD,CA,CA,2021,Q1,Elderly
190017741,19001774,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210222.0,20210312,20210312,EXP,,CA-JNJFOC-20210316789,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210312.0,,MD,CA,CA,2021,Q1,Elderly
190017741,19001774,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,1,I,,20210222.0,20210312,20210312,EXP,,CA-JNJFOC-20210316789,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210312.0,,MD,CA,CA,2021,Q1,Elderly
190017741,19001774,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,,20210222.0,20210312,20210312,EXP,,CA-JNJFOC-20210316789,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210312.0,,MD,CA,CA,2021,Q1,Elderly
190017741,19001774,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q1,Type 2 diabetes mellitus,,2021,Q1,1,I,,20210222.0,20210312,20210312,EXP,,CA-JNJFOC-20210316789,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210312.0,,MD,CA,CA,2021,Q1,Elderly
190281581,19028158,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2021,Q1,Dizziness,,2021,Q1,1,I,20210226.0,20210311.0,20210319,20210319,EXP,ES-AEMPS-778293,ES-JNJFOC-20210319468,JOHNSON AND JOHNSON,,51.0,YR,A,F,Y,,,20210319.0,,PH,ES,ES,2021,Q1,Adult
190281581,19028158,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,U,U,,,204353.0,,,TABLET,,2021,Q1,Nausea,,2021,Q1,1,I,20210226.0,20210311.0,20210319,20210319,EXP,ES-AEMPS-778293,ES-JNJFOC-20210319468,JOHNSON AND JOHNSON,,51.0,YR,A,F,Y,,,20210319.0,,PH,ES,ES,2021,Q1,Adult
190505051,19050505,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Drug interaction,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-AUROBINDO-AUR-APL-2021-011455,AUROBINDO,,76.0,YR,,F,Y,,,20210324.0,,MD,CA,CA,2021,Q1,Elderly
190505051,19050505,2,I,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2021,Q1,Myopathy toxic,,2021,Q1,1,I,,20210315.0,20210324,20210324,EXP,,CA-AUROBINDO-AUR-APL-2021-011455,AUROBINDO,,76.0,YR,,F,Y,,,20210324.0,,MD,CA,CA,2021,Q1,Elderly
190564501,19056450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Acute kidney injury,,2021,Q1,1,I,201712.0,20210316.0,20210325,20210325,EXP,,GB-EMD SERONO-9226688,EMD SERONO INC,"DAVIES E, SALEH C, BANNARD?SMITH J. RECOVERY FROM PROFOUND ACIDOSIS (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME.. JOURNAL OF THE INTENSIVE CARE SOCIETY.. 2021 FEB 01?22(1):78?82. DOI:10.1177/1751143719870102",49.0,YR,A,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Adult
190564501,19056450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Lactic acidosis,,2021,Q1,1,I,201712.0,20210316.0,20210325,20210325,EXP,,GB-EMD SERONO-9226688,EMD SERONO INC,"DAVIES E, SALEH C, BANNARD?SMITH J. RECOVERY FROM PROFOUND ACIDOSIS (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME.. JOURNAL OF THE INTENSIVE CARE SOCIETY.. 2021 FEB 01?22(1):78?82. DOI:10.1177/1751143719870102",49.0,YR,A,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Adult
190564501,19056450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Metabolic acidosis,,2021,Q1,1,I,201712.0,20210316.0,20210325,20210325,EXP,,GB-EMD SERONO-9226688,EMD SERONO INC,"DAVIES E, SALEH C, BANNARD?SMITH J. RECOVERY FROM PROFOUND ACIDOSIS (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME.. JOURNAL OF THE INTENSIVE CARE SOCIETY.. 2021 FEB 01?22(1):78?82. DOI:10.1177/1751143719870102",49.0,YR,A,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Adult
190564501,19056450,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q1,Multiple organ dysfunction syndrome,,2021,Q1,1,I,201712.0,20210316.0,20210325,20210325,EXP,,GB-EMD SERONO-9226688,EMD SERONO INC,"DAVIES E, SALEH C, BANNARD?SMITH J. RECOVERY FROM PROFOUND ACIDOSIS (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME.. JOURNAL OF THE INTENSIVE CARE SOCIETY.. 2021 FEB 01?22(1):78?82. DOI:10.1177/1751143719870102",49.0,YR,A,F,Y,,,20210325.0,,HP,GB,GB,2021,Q1,Adult
190648761,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Asthma,,2021,Q1,1,I,,20210311.0,20210326,20210326,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210326.0,,MD,CA,CA,2021,Q1,Elderly
190648761,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210311.0,20210326,20210326,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210326.0,,MD,CA,CA,2021,Q1,Elderly
190648761,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,1,I,,20210311.0,20210326,20210326,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210326.0,,MD,CA,CA,2021,Q1,Elderly
190648761,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,,20210311.0,20210326,20210326,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210326.0,,MD,CA,CA,2021,Q1,Elderly
190648761,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q1,Type 2 diabetes mellitus,,2021,Q1,1,I,,20210311.0,20210326,20210326,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210326.0,,MD,CA,CA,2021,Q1,Elderly
190755841,19075584,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Asthma,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010421,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,CN,CA,CA,2021,Q1,Elderly
190755841,19075584,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010421,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,CN,CA,CA,2021,Q1,Elderly
190755841,19075584,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010421,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,CN,CA,CA,2021,Q1,Elderly
190755841,19075584,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010421,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,CN,CA,CA,2021,Q1,Elderly
190755841,19075584,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Type 2 diabetes mellitus,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010421,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,CN,CA,CA,2021,Q1,Elderly
190755881,19075588,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Asthma,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010459,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,MD,CA,CA,2021,Q1,Elderly
190755881,19075588,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Blood count abnormal,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010459,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,MD,CA,CA,2021,Q1,Elderly
190755881,19075588,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Gastrooesophageal reflux disease,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010459,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,MD,CA,CA,2021,Q1,Elderly
190755881,19075588,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Hyperglycaemia,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010459,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,MD,CA,CA,2021,Q1,Elderly
190755881,19075588,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q1,Type 2 diabetes mellitus,,2021,Q1,1,I,,20210322.0,20210330,20210330,EXP,,CA-BAUSCH-BL-2021-010459,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210330.0,,MD,CA,CA,2021,Q1,Elderly
144585187,14458518,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q2,Asthma,,2021,Q2,7,F,,20210517.0,20180130,20210527,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210527.0,,CN,CA,CA,2021,Q2,Elderly
144585187,14458518,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q2,Blood count abnormal,,2021,Q2,7,F,,20210517.0,20180130,20210527,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210527.0,,CN,CA,CA,2021,Q2,Elderly
144585187,14458518,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q2,Gastrooesophageal reflux disease,,2021,Q2,7,F,,20210517.0,20180130,20210527,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210527.0,,CN,CA,CA,2021,Q2,Elderly
144585187,14458518,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q2,Hyperglycaemia,,2021,Q2,7,F,,20210517.0,20180130,20210527,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210527.0,,CN,CA,CA,2021,Q2,Elderly
144585187,14458518,26,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q2,Type 2 diabetes mellitus,,2021,Q2,7,F,,20210517.0,20180130,20210527,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210527.0,,CN,CA,CA,2021,Q2,Elderly
147511827,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNKNOWN",,,D,,,,,300.0,MG,,,2021,Q2,Cardiac failure acute,,2021,Q2,7,F,20170602.0,20210428.0,20180412,20210430,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20210430.0,,MD,CA,CA,2021,Q2,Adult
147511827,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNKNOWN",,,D,,,,,300.0,MG,,,2021,Q2,Cellulitis,,2021,Q2,7,F,20170602.0,20210428.0,20180412,20210430,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20210430.0,,MD,CA,CA,2021,Q2,Adult
147511827,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNKNOWN",,,D,,,,,300.0,MG,,,2021,Q2,Prescribed overdose,,2021,Q2,7,F,20170602.0,20210428.0,20180412,20210430,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20210430.0,,MD,CA,CA,2021,Q2,Adult
147511827,14751182,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, UNKNOWN",,,D,,,,,300.0,MG,,,2021,Q2,Psoriasis,,2021,Q2,7,F,20170602.0,20210428.0,20180412,20210430,EXP,,PHHY2018CA063716,NOVARTIS,,53.0,YR,,M,Y,141.0,KG,20210430.0,,MD,CA,CA,2021,Q2,Adult
179886773,17988677,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,300 MILLIGRAM DAILY;,,,U,,,,,300.0,MG,,QD,2021,Q2,Labile blood pressure,,2021,Q2,3,F,,20200721.0,20200707,20210629,EXP,,US-TEVA-2020-US-1796955,TEVA,"SETHI P, CHANG GV, GOWDA SN, ELNAIR R, FENNER R, LAMFERS R. RECURRENT CATECHOLAMINE?INDUCED CARDIOMYOPATHY AND HYPERTENSIVE EMERGENCIES: A PRESENTATION OF PHEOCHROMOCYTOMA AND RELATED CONCERNS. S?D?MED 2020?73(2):78?80.",51.0,YR,A,F,Y,,,20210629.0,,MD,US,US,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Blood pressure diastolic increased,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Blood pressure fluctuation,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Condition aggravated,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Flushing,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Heart rate irregular,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Hypertension,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Inappropriate schedule of product administration,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Off label use,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Oropharyngeal discomfort,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Pneumonia,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
183988602,18398860,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,500.0,MG,,,2021,Q2,Tachycardia,,2021,Q2,2,F,,20210428.0,20201019,20210506,EXP,,CA-SAMSUNG BIOEPIS-SB-2020-31708,SAMSUNG BIOEPIS,,44.0,YR,A,F,Y,95.0,KG,20210506.0,,HP,CA,CA,2021,Q2,Adult
184411892,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Arteriosclerosis coronary artery,,2021,Q2,2,F,20201008.0,20210329.0,20201029,20210407,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20210407.0,,MD,BR,BR,2021,Q2,Elderly
184411892,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Hyperglycaemia,,2021,Q2,2,F,20201008.0,20210329.0,20201029,20210407,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20210407.0,,MD,BR,BR,2021,Q2,Elderly
184411892,18441189,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,30 MG,,,,, UNKNOWN,,,,,,,2021,Q2,Hypoglycaemia,,2021,Q2,2,F,20201008.0,20210329.0,20201029,20210407,EXP,,BR-NOVOPROD-762119,NOVO NORDISK,,78.0,YR,,M,Y,81.0,KG,20210407.0,,MD,BR,BR,2021,Q2,Elderly
184528042,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Asthma,,2021,Q2,2,F,,20210406.0,20201102,20210412,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210412.0,,MD,CA,CA,2021,Q2,Elderly
184528042,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Blood count abnormal,,2021,Q2,2,F,,20210406.0,20201102,20210412,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210412.0,,MD,CA,CA,2021,Q2,Elderly
184528042,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Gastrooesophageal reflux disease,,2021,Q2,2,F,,20210406.0,20201102,20210412,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210412.0,,MD,CA,CA,2021,Q2,Elderly
184528042,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Hyperglycaemia,,2021,Q2,2,F,,20210406.0,20201102,20210412,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210412.0,,MD,CA,CA,2021,Q2,Elderly
184528042,18452804,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Type 2 diabetes mellitus,,2021,Q2,2,F,,20210406.0,20201102,20210412,EXP,,CA-JNJFOC-20201050571,JOHNSON AND JOHNSON,,76.0,YR,E,F,Y,,,20210412.0,,MD,CA,CA,2021,Q2,Elderly
185109152,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Cerebral infarction,,2021,Q2,2,F,20200914.0,20210415.0,20201117,20210426,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20210426.0,,MD,JP,JP,2021,Q2,Elderly
185109152,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,2,F,20200914.0,20210415.0,20201117,20210426,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20210426.0,,MD,JP,JP,2021,Q2,Elderly
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Abdominal discomfort,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Abdominal pain,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Acne,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Adverse drug reaction,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Anogenital warts,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Back pain,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Cellulitis,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Condition aggravated,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Constipation,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Cyst,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Diabetes mellitus,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Diarrhoea,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Eating disorder,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Fibromyalgia,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Herpes zoster,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Illness,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Immune system disorder,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Impetigo,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Joint range of motion decreased,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Mass,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Memory impairment,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Rosacea,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Skin lesion,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Speech disorder,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
185546775,18554677,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,1 TABLET AT NOON,,,,,,,,100.0,MG,TABLET,QD,2021,Q2,Unevaluable event,,2021,Q2,5,F,2019.0,20210415.0,20201127,20210423,EXP,,CA-ABBVIE-20K-028-3664566-00,ABBVIE,,51.0,YR,,F,Y,96.0,KG,20210423.0,,MD,CA,CA,2021,Q2,Adult
186108812,18610881,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Nephritis bacterial,,2021,Q2,2,F,20201125.0,20210617.0,20201214,20210627,EXP,,JP-JNJFOC-20201216273,JOHNSON AND JOHNSON,,60.0,YR,A,F,Y,,,20210628.0,,MD,JP,JP,2021,Q2,Adult
186401845,18640184,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",1370.833,MG,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Liver disorder,,2021,Q2,5,F,20201127.0,20210324.0,20201220,20210404,EXP,,JP-JNJFOC-20201233398,JOHNSON AND JOHNSON,,42.0,YR,A,M,Y,,,20210404.0,,MD,JP,JP,2021,Q2,Adult
186401845,18640184,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",1370.833,MG,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Urinary tract infection,,2021,Q2,5,F,20201127.0,20210324.0,20201220,20210404,EXP,,JP-JNJFOC-20201233398,JOHNSON AND JOHNSON,,42.0,YR,A,M,Y,,,20210404.0,,MD,JP,JP,2021,Q2,Adult
188278083,18827808,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,204042.0,,,TABLET,,2021,Q2,Haemorrhage subcutaneous,,2021,Q2,3,F,,20210409.0,20210202,20210421,EXP,,JP-JNJFOC-20210146209,JOHNSON AND JOHNSON,,72.0,YR,E,M,Y,,,20210421.0,,PH,JP,JP,2021,Q2,Elderly
188376302,18837630,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",300.0,MG,,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Hepatic function abnormal,,2021,Q2,2,F,20210102.0,20210331.0,20210203,20210412,EXP,,JP-JNJFOC-20210203239,JOHNSON AND JOHNSON,,71.0,YR,E,M,Y,,,20210412.0,,MD,JP,JP,2021,Q2,Elderly
188683523,18868352,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",8900.0,MG,Y,,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Fournier's gangrene,,2021,Q2,3,F,20200622.0,20210408.0,20210209,20210421,EXP,,JP-JNJFOC-20210214244,JOHNSON AND JOHNSON,,61.0,YR,A,M,Y,,,20210421.0,,PH,JP,JP,2021,Q2,Adult
189082263,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Off label use,,2021,Q2,3,F,20190204.0,20210513.0,20210218,20210524,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",68.0,YR,E,M,Y,,,20210524.0,,MD,JP,JP,2021,Q2,Elderly
189082263,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Pulmonary artery thrombosis,,2021,Q2,3,F,20190204.0,20210513.0,20210218,20210524,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",68.0,YR,E,M,Y,,,20210524.0,,MD,JP,JP,2021,Q2,Elderly
189082263,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Venous thrombosis limb,,2021,Q2,3,F,20190204.0,20210513.0,20210218,20210524,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",68.0,YR,E,M,Y,,,20210524.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",19000.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Pancreatitis acute,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",19000.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,19000.0,MG,U,U,,,204042.0,,,TABLET,,2021,Q2,Pancreatitis acute,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,19000.0,MG,U,U,,,204042.0,,,TABLET,,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,3,SS,CANAGLIFLOZIN;TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"UNK, QD",,,N,,,,,,,TABLET,QD,2021,Q2,Pancreatitis acute,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
189210793,18921079,3,SS,CANAGLIFLOZIN;TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"UNK, QD",,,N,,,,,,,TABLET,QD,2021,Q2,Therapeutic product effect incomplete,,2021,Q2,3,F,20210209.0,20210330.0,20210222,20210408,EXP,,JP-JNJFOC-20210233504,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20210408.0,,MD,JP,JP,2021,Q2,Elderly
190631762,19063176,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,UNK,,2021,Q2,Asthma,,2021,Q2,2,F,,20210311.0,20210326,20210417,EXP,,CA-TAKEDA-2021TUS016801,TAKEDA,,76.0,YR,,F,Y,,,20210417.0,,CN,CA,CA,2021,Q2,Elderly
190631762,19063176,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,UNK,,2021,Q2,Blood count abnormal,,2021,Q2,2,F,,20210311.0,20210326,20210417,EXP,,CA-TAKEDA-2021TUS016801,TAKEDA,,76.0,YR,,F,Y,,,20210417.0,,CN,CA,CA,2021,Q2,Elderly
190631762,19063176,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,UNK,,2021,Q2,Gastrooesophageal reflux disease,,2021,Q2,2,F,,20210311.0,20210326,20210417,EXP,,CA-TAKEDA-2021TUS016801,TAKEDA,,76.0,YR,,F,Y,,,20210417.0,,CN,CA,CA,2021,Q2,Elderly
190631762,19063176,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,UNK,,2021,Q2,Hyperglycaemia,,2021,Q2,2,F,,20210311.0,20210326,20210417,EXP,,CA-TAKEDA-2021TUS016801,TAKEDA,,76.0,YR,,F,Y,,,20210417.0,,CN,CA,CA,2021,Q2,Elderly
190631762,19063176,5,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,UNK,,2021,Q2,Type 2 diabetes mellitus,,2021,Q2,2,F,,20210311.0,20210326,20210417,EXP,,CA-TAKEDA-2021TUS016801,TAKEDA,,76.0,YR,,F,Y,,,20210417.0,,CN,CA,CA,2021,Q2,Elderly
190648762,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q2,Asthma,,2021,Q2,2,F,,20210417.0,20210326,20210426,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210426.0,,MD,CA,CA,2021,Q2,Elderly
190648762,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q2,Blood count abnormal,,2021,Q2,2,F,,20210417.0,20210326,20210426,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210426.0,,MD,CA,CA,2021,Q2,Elderly
190648762,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q2,Gastrooesophageal reflux disease,,2021,Q2,2,F,,20210417.0,20210326,20210426,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210426.0,,MD,CA,CA,2021,Q2,Elderly
190648762,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q2,Hyperglycaemia,,2021,Q2,2,F,,20210417.0,20210326,20210426,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210426.0,,MD,CA,CA,2021,Q2,Elderly
190648762,19064876,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,,,2021,Q2,Type 2 diabetes mellitus,,2021,Q2,2,F,,20210417.0,20210326,20210426,EXP,,CA-PFIZER INC-2021334954,PFIZER,,76.0,YR,,F,Y,,,20210426.0,,MD,CA,CA,2021,Q2,Elderly
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Asthenia,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Dermatitis allergic,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Gastroenteritis,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Nausea,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Pruritus,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Rash,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190716902,19071690,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1000.0,MG,Y,U, KEL1G00,,,100.0,MG,TABLET,QD,2021,Q2,Vomiting,,2021,Q2,2,F,20210301.0,20210401.0,20210330,20210413,EXP,CN-NMPA-3305011058938202100117,CN-NOVOPROD-798028,NOVO NORDISK,,54.0,YR,,F,Y,70.0,KG,20210413.0,,HP,CN,CN,2021,Q2,Adult
190813611,19081361,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q2,Acute myocardial infarction,,2021,Q2,1,I,20201128.0,20210326.0,20210401,20210401,EXP,GB-MHRA-EYC 00245248,GB-JNJFOC-20210356747,JOHNSON AND JOHNSON,,55.0,YR,A,M,Y,,,20210401.0,,MD,GB,GB,2021,Q2,Adult
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Drug interaction,Drug interaction,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Drug level above therapeutic,Drug level above therapeutic,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hepatocellular injury,Hepatocellular injury,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Myopathy toxic,Myopathy toxic,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Renal impairment,Renal impairment,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
190868451,19086845,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Rhabdomyolysis,Rhabdomyolysis,2021,Q2,1,I,,20210322.0,20210402,20210402,EXP,,SA-RNT-000021,RENATA LIMITED,,76.0,YR,E,F,Y,,,20210402.0,,HP,US,SA,2021,Q2,Elderly
191512731,19151273,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,TABLET,,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,20210410.0,20210414.0,20210419,20210419,EXP,GB-MHRA-EYC 00247537,GB-JNJFOC-20210429446,JOHNSON AND JOHNSON,,73.0,YR,E,M,Y,,,20210419.0,,PH,GB,GB,2021,Q2,Elderly
191838011,19183801,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,100.0,MG,TABLET,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210419.0,20210427,20210427,EXP,,PT-JNJFOC-20210441096,JOHNSON AND JOHNSON,"MONTEIRO?SANTOS M, FERREIRA C, BRITO D, ELIAS T. EUGLICEMIC DIABETIC KETOACIDOSIS, AN EASILY MISSED DIAGNOSIS. GALICIA CLIN. 2021?82?1:36?37.",61.0,YR,A,M,Y,,,20210427.0,,HP,PT,PT,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Bedridden,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Gastric disorder,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Headache,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Hyperhidrosis,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Nausea,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192021241,19202124,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,100 MG,,,,,,,,100.0,MG,,,2021,Q2,Pain,,2021,Q2,1,I,20210412.0,20210422.0,20210430,20210430,EXP,GB-MHRA-EYC 00248079,GB-TEVA-2021-GB-1906012,TEVA,,56.0,YR,A,F,Y,95.25,KG,20210430.0,,CN,GB,GB,2021,Q2,Adult
192122281,19212228,4,C,canagliflozin 300mg daily,,2,,,,,,,,,,,,,,2021,Q2,Cardiac arrest,,2021,Q2,1,I,20210428.0,,20210504,20210504,DIR,,,FDA-CTU,,65.0,YR,,M,N,105.0,KG,20210504.0,N,PH,US,US,2021,Q2,Elderly
192123381,19212338,3,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,U,,,,100.0,MG,TABLET,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210503.0,20210504,20210504,EXP,,PT-AUROBINDO-AUR-APL-2021-018527,AUROBINDO,,61.0,YR,,M,Y,,,20210504.0,,HP,PT,PT,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Acute kidney injury,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Acute respiratory failure,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Lactic acidosis,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Multi-organ disorder,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192124531,19212453,2,C,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q2,Tracheostomy,,2021,Q2,1,I,,20210419.0,20210504,20210504,EXP,,"GB-NOSTRUM LABORATORIES, INC.-2110183",NOSTRUM,"DAVIES E.A., ET AL., ^RECOVERY FROM PROFOUND ACIDOSIS, (PH 6.685) IN MULTI?ORGAN DYSFUNCTION SYNDROME^, JOURNAL OF THE INTENSIVE CARE SOCIETY 2021, VOL. 22(1): 78 ? 82.",49.0,YR,,F,Y,,,20210504.0,,MD,GB,GB,2021,Q2,Adult
192271151,19227115,9,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,100.0,MG,UNK,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210428.0,20210507,20210507,EXP,,JP-GRANULES-JP-2021GRALIT00273,GRANULES INDIA,,72.0,YR,E,M,Y,,,20210507.0,,HP,JP,JP,2021,Q2,Elderly
192271151,19227115,9,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNKNOWN,,,100.0,MG,UNK,,2021,Q2,Liver abscess,,2021,Q2,1,I,,20210428.0,20210507,20210507,EXP,,JP-GRANULES-JP-2021GRALIT00273,GRANULES INDIA,,72.0,YR,E,M,Y,,,20210507.0,,HP,JP,JP,2021,Q2,Elderly
192342262,19234226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Death,,2021,Q2,2,F,,20210513.0,20210508,20210525,EXP,,JP-JNJFOC-20210512716,JOHNSON AND JOHNSON,,3.0,DEC,A,,Y,,,20210526.0,,PH,JP,JP,2021,Q2,Child
192342262,19234226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Ketoacidosis,,2021,Q2,2,F,,20210513.0,20210508,20210525,EXP,,JP-JNJFOC-20210512716,JOHNSON AND JOHNSON,,3.0,DEC,A,,Y,,,20210526.0,,PH,JP,JP,2021,Q2,Child
192342262,19234226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Multiple organ dysfunction syndrome,,2021,Q2,2,F,,20210513.0,20210508,20210525,EXP,,JP-JNJFOC-20210512716,JOHNSON AND JOHNSON,,3.0,DEC,A,,Y,,,20210526.0,,PH,JP,JP,2021,Q2,Child
192519771,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"TAKE ONE DAILY, PREFERABLY BEFORE BREAKFAST",,,,,,,,,,UNKNOWN,,2021,Q2,Adverse drug reaction,,2021,Q2,1,I,20210504.0,20210505.0,20210513,20210513,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20210513.0,,PH,GB,GB,2021,Q2,Elderly
192519771,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"TAKE ONE DAILY, PREFERABLY BEFORE BREAKFAST",,,,,,,,,,UNKNOWN,,2021,Q2,Glomerular filtration rate decreased,,2021,Q2,1,I,20210504.0,20210505.0,20210513,20210513,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20210513.0,,PH,GB,GB,2021,Q2,Elderly
192519771,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"TAKE ONE DAILY, PREFERABLY BEFORE BREAKFAST",,,,,,,,,,UNKNOWN,,2021,Q2,Off label use,,2021,Q2,1,I,20210504.0,20210505.0,20210513,20210513,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20210513.0,,PH,GB,GB,2021,Q2,Elderly
192519771,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"TAKE ONE DAILY, PREFERABLY BEFORE BREAKFAST",,,,,,,,,,UNKNOWN,,2021,Q2,Product use in unapproved indication,,2021,Q2,1,I,20210504.0,20210505.0,20210513,20210513,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20210513.0,,PH,GB,GB,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Acute kidney injury,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Asthenia,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Blood glucose abnormal,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Dysstasia,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Fatigue,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Hypophagia,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
192977891,19297789,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2021,Q2,Malaise,,2021,Q2,1,I,,20210517.0,20210524,20210524,EXP,,CA-JNJFOC-20210536902,JOHNSON AND JOHNSON,,65.0,YR,E,M,Y,,,20210524.0,,PH,CA,CA,2021,Q2,Elderly
193322861,19332286,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Renal impairment,,2021,Q2,1,I,,20210520.0,20210529,20210529,EXP,,JP-JNJFOC-20210548625,JOHNSON AND JOHNSON,,8.0,DEC,E,M,Y,,,20210528.0,,PH,JP,JP,2021,Q2,Child
193495691,19349569,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Emphysematous cystitis,,2021,Q2,1,I,,20210521.0,20210531,20210531,EXP,,JP-JNJFOC-20210554182,JOHNSON AND JOHNSON,KATO K. P ?25 ?3 EMPHYSEMATOUS CYSTITIS DURING ORAL THERAPY WITH SGLT2 INHIBITORS. THE 64TH ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY. THE 64TH MEETING OF THE JAPAN DIABETES SOCIETY. 2021,57.0,YR,A,F,Y,,,20210531.0,,MD,JP,JP,2021,Q2,Adult
193495691,19349569,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Pyelonephritis,,2021,Q2,1,I,,20210521.0,20210531,20210531,EXP,,JP-JNJFOC-20210554182,JOHNSON AND JOHNSON,KATO K. P ?25 ?3 EMPHYSEMATOUS CYSTITIS DURING ORAL THERAPY WITH SGLT2 INHIBITORS. THE 64TH ANNUAL MEETING OF THE JAPAN DIABETES SOCIETY. THE 64TH MEETING OF THE JAPAN DIABETES SOCIETY. 2021,57.0,YR,A,F,Y,,,20210531.0,,MD,JP,JP,2021,Q2,Adult
193649641,19364964,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Off label use,,2021,Q2,1,I,,20210525.0,20210602,20210602,EXP,,TW-JNJFOC-20210553358,JOHNSON AND JOHNSON,"FONG M.?C., FENG A.?N., YIN W.?H., TSAO T.?P., CHANG H.?Y.,  DEFIBRILLATION THERAPIES FOLLOWING SODIUM?GLUCOSE COTRANSPORTER 2 INHIBITOR TREATMENT: A REPORT OF TWO CASES HEARTRHYTHM CASE REPORTS 2021 7 338?342",64.0,YR,A,M,Y,,,20210602.0,,MD,TW,TW,2021,Q2,Adult
193649641,19364964,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Product use issue,,2021,Q2,1,I,,20210525.0,20210602,20210602,EXP,,TW-JNJFOC-20210553358,JOHNSON AND JOHNSON,"FONG M.?C., FENG A.?N., YIN W.?H., TSAO T.?P., CHANG H.?Y.,  DEFIBRILLATION THERAPIES FOLLOWING SODIUM?GLUCOSE COTRANSPORTER 2 INHIBITOR TREATMENT: A REPORT OF TWO CASES HEARTRHYTHM CASE REPORTS 2021 7 338?342",64.0,YR,A,M,Y,,,20210602.0,,MD,TW,TW,2021,Q2,Adult
193649641,19364964,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Ventricular fibrillation,,2021,Q2,1,I,,20210525.0,20210602,20210602,EXP,,TW-JNJFOC-20210553358,JOHNSON AND JOHNSON,"FONG M.?C., FENG A.?N., YIN W.?H., TSAO T.?P., CHANG H.?Y.,  DEFIBRILLATION THERAPIES FOLLOWING SODIUM?GLUCOSE COTRANSPORTER 2 INHIBITOR TREATMENT: A REPORT OF TWO CASES HEARTRHYTHM CASE REPORTS 2021 7 338?342",64.0,YR,A,M,Y,,,20210602.0,,MD,TW,TW,2021,Q2,Adult
193735631,19373563,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNK,,,,,TABLET,,2021,Q2,Blood creatine increased,,2021,Q2,1,I,,20210602.0,20210603,20210603,EXP,,CA-FRESENIUS KABI-FK202105648,FRESENIUS KABI,,60.0,YR,,M,Y,161.0,KG,20210603.0,,PH,CA,CA,2021,Q2,Adult
193735631,19373563,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNK,,,,,TABLET,,2021,Q2,Deafness bilateral,,2021,Q2,1,I,,20210602.0,20210603,20210603,EXP,,CA-FRESENIUS KABI-FK202105648,FRESENIUS KABI,,60.0,YR,,M,Y,161.0,KG,20210603.0,,PH,CA,CA,2021,Q2,Adult
193735631,19373563,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNK,,,,,TABLET,,2021,Q2,Tinnitus,,2021,Q2,1,I,,20210602.0,20210603,20210603,EXP,,CA-FRESENIUS KABI-FK202105648,FRESENIUS KABI,,60.0,YR,,M,Y,161.0,KG,20210603.0,,PH,CA,CA,2021,Q2,Adult
193735631,19373563,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,, UNK,,,,,TABLET,,2021,Q2,Vertigo,,2021,Q2,1,I,,20210602.0,20210603,20210603,EXP,,CA-FRESENIUS KABI-FK202105648,FRESENIUS KABI,,60.0,YR,,M,Y,161.0,KG,20210603.0,,PH,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Alanine aminotransferase increased,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Aspartate aminotransferase increased,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Dyspnoea,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Hypoventilation,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Interstitial lung disease,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Joint swelling,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Limb mass,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Off label use,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Peripheral swelling,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Product use in unapproved indication,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Rash pruritic,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Raynaud's phenomenon,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193801641,19380164,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, QD",,,D,,,,,300.0,MG,,,2021,Q2,Weight increased,,2021,Q2,1,I,,20210526.0,20210607,20210607,EXP,,CA-APOTEX-2021AP012981,APOTEX,,48.0,YR,,M,Y,,,20210607.0,,CN,CA,CA,2021,Q2,Adult
193932461,19393246,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Diabetic ketoacidosis,,2021,Q2,1,I,,20210525.0,20210609,20210609,EXP,,IL-JNJFOC-20210614426,JOHNSON AND JOHNSON,"ABU?AMER N, MINI S, BECKERMAN P, DINOUR D. AN UNUSUAL CASE OF METABOLIC ACIDOSIS: CLINICAL CASE EDUCATION. ISR MED ASSOC J. 2019 NOV?21:766?768.",58.0,YR,A,F,Y,,,20210609.0,,HP,IL,IL,2021,Q2,Adult
193932461,19393246,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Glycosuria,,2021,Q2,1,I,,20210525.0,20210609,20210609,EXP,,IL-JNJFOC-20210614426,JOHNSON AND JOHNSON,"ABU?AMER N, MINI S, BECKERMAN P, DINOUR D. AN UNUSUAL CASE OF METABOLIC ACIDOSIS: CLINICAL CASE EDUCATION. ISR MED ASSOC J. 2019 NOV?21:766?768.",58.0,YR,A,F,Y,,,20210609.0,,HP,IL,IL,2021,Q2,Adult
193933271,19393327,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Euglycaemic diabetic ketoacidosis,,2021,Q2,1,I,,20210525.0,20210609,20210609,EXP,,US-JNJFOC-20210614257,JOHNSON AND JOHNSON,"DAI Y, COHEN R. SUN?183 PROLONGED GLYCOSURIA AFTER CANAGLIFLOZIN DISCONTINUATION IN A PATIENT WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. JOURNAL OF THE ENDOCRINE SOCIETY. 2019?3(1):.",52.0,YR,A,F,Y,,,20210609.0,,MD,US,US,2021,Q2,Adult
193933271,19393327,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,,,TABLET,,2021,Q2,Glycosuria,,2021,Q2,1,I,,20210525.0,20210609,20210609,EXP,,US-JNJFOC-20210614257,JOHNSON AND JOHNSON,"DAI Y, COHEN R. SUN?183 PROLONGED GLYCOSURIA AFTER CANAGLIFLOZIN DISCONTINUATION IN A PATIENT WITH EUGLYCEMIC DIABETIC KETOACIDOSIS. JOURNAL OF THE ENDOCRINE SOCIETY. 2019?3(1):.",52.0,YR,A,F,Y,,,20210609.0,,MD,US,US,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Anal abscess,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Device infusion issue,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Injection site mass,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Injection site oedema,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Injection site pain,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194071392,19407139,14,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Injection site swelling,,2021,Q2,2,F,202102.0,20210610.0,20210611,20210621,EXP,,CA-TAKEDA-2021TUS035052,TAKEDA,,63.0,YR,,M,Y,108.84,KG,20210621.0,,HP,CA,CA,2021,Q2,Adult
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Arthralgia,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood pressure diastolic abnormal,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood pressure diastolic decreased,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood pressure fluctuation,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Blood pressure increased,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Breast disorder,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Contusion,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Cystitis,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Fall,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Fibromyalgia,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Finger deformity,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Heart rate increased,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hypertension,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hypotension,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Hypothyroidism,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Intentional product use issue,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Intercepted medication error,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Kidney infection,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Lower respiratory tract infection,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Nasopharyngitis,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Nodule,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Oxygen saturation decreased,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Pain,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Rheumatoid arthritis,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Steroid diabetes,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Urinary tract infection,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Vascular stenosis,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194165041,19416504,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210607.0,20210614,20210614,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-055991,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20210614.0,,CN,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Drug interaction,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Drug-induced liver injury,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Hepatocellular injury,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Musculoskeletal toxicity,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194193871,19419387,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Toxicity to various agents,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921721,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194195221,19419522,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Drug interaction,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921697,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194195221,19419522,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Hepatocellular injury,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921697,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194195221,19419522,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Muscle disorder,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921697,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194195221,19419522,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,,20210607.0,20210615,20210615,EXP,,CA-TEVA-2021-CA-1921697,TEVA,,76.0,YR,E,F,Y,,,20210615.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Drug interaction,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Drug level increased,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Gait disturbance,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Hepatocellular injury,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Laboratory test abnormal,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194205411,19420541,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,QD,2021,Q2,Toxicity to various agents,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921695,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,HP,CA,CA,2021,Q2,Elderly
194206241,19420624,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,,2021,Q2,Drug interaction,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921740,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,MD,CA,CA,2021,Q2,Elderly
194206241,19420624,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,,2021,Q2,Drug level above therapeutic,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921740,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,MD,CA,CA,2021,Q2,Elderly
194206241,19420624,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,,2021,Q2,Hepatocellular injury,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921740,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,MD,CA,CA,2021,Q2,Elderly
194206241,19420624,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,,2021,Q2,Rhabdomyolysis,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921740,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,MD,CA,CA,2021,Q2,Elderly
194206241,19420624,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,100 MILLIGRAM DAILY;,,,U,,,,,100.0,MG,,,2021,Q2,Toxicity to various agents,,2021,Q2,1,I,,20210607.0,20210616,20210616,EXP,,CA-TEVA-2021-CA-1921740,TEVA,,76.0,YR,E,F,Y,,,20210616.0,,MD,CA,CA,2021,Q2,Elderly
194294261,19429426,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q2,Myocarditis,,2021,Q2,1,I,,20210604.0,20210617,20210617,EXP,CA-MHPD-E2B03415870,CA-ACCORD-227987,ACCORD,,61.0,YR,,M,Y,,,20210617.0,,HP,CA,CA,2021,Q2,Adult
194407141,19440714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Cardiovascular disorder,,2021,Q2,1,I,,20210611.0,20210621,20210621,EXP,,JP-JNJFOC-20210637473,JOHNSON AND JOHNSON,,90.0,YR,E,M,Y,,,20210621.0,,PH,JP,JP,2021,Q2,Elderly
194407141,19440714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Glucose urine present,,2021,Q2,1,I,,20210611.0,20210621,20210621,EXP,,JP-JNJFOC-20210637473,JOHNSON AND JOHNSON,,90.0,YR,E,M,Y,,,20210621.0,,PH,JP,JP,2021,Q2,Elderly
194407141,19440714,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210611.0,20210621,20210621,EXP,,JP-JNJFOC-20210637473,JOHNSON AND JOHNSON,,90.0,YR,E,M,Y,,,20210621.0,,PH,JP,JP,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Arthralgia,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Blood pressure diastolic abnormal,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Blood pressure diastolic decreased,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Blood pressure fluctuation,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Blood pressure increased,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Breast disorder,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Contusion,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Cystitis,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Drug ineffective,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Fall,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Fibromyalgia,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Finger deformity,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Heart rate increased,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Hypertension,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Hypotension,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Hypothyroidism,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Intentional product use issue,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Intercepted medication error,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Kidney infection,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Lower respiratory tract infection,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Nasopharyngitis,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Nodule,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Oxygen saturation decreased,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Pain,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Rheumatoid arthritis,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Steroid diabetes,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Urinary tract infection,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Vascular stenosis,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194435211,19443521,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q2,Weight decreased,,2021,Q2,1,I,,20210607.0,20210621,20210621,EXP,,CA-PFIZER INC-2021707860,PFIZER,,67.0,YR,,F,Y,69.0,KG,20210621.0,,CN,CA,CA,2021,Q2,Elderly
194730541,19473054,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DOSAGE FORM, PREFERABLY BEFORE BREAKFAST",244.0,DF,,,,,,1.0,DF,,QD,2021,Q2,Hypokalaemia,,2021,Q2,1,I,20210622.0,20210624.0,20210629,20210629,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-MYLANLABS-2021M1038224,MYLAN,,66.0,YR,,F,Y,64.0,KG,20210629.0,,PH,GB,GB,2021,Q2,Elderly
194730541,19473054,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DOSAGE FORM, PREFERABLY BEFORE BREAKFAST",244.0,DF,,,,,,1.0,DF,,QD,2021,Q2,Palpitations,,2021,Q2,1,I,20210622.0,20210624.0,20210629,20210629,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-MYLANLABS-2021M1038224,MYLAN,,66.0,YR,,F,Y,64.0,KG,20210629.0,,PH,GB,GB,2021,Q2,Elderly
194730541,19473054,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DOSAGE FORM, PREFERABLY BEFORE BREAKFAST",244.0,DF,,,,,,1.0,DF,,QD,2021,Q2,Product substitution issue,,2021,Q2,1,I,20210622.0,20210624.0,20210629,20210629,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-MYLANLABS-2021M1038224,MYLAN,,66.0,YR,,F,Y,64.0,KG,20210629.0,,PH,GB,GB,2021,Q2,Elderly
194766581,19476658,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2021,Q2,Pancreatic carcinoma,,2021,Q2,1,I,201806.0,20210623.0,20210630,20210630,EXP,,JP-JNJFOC-20210666252,JOHNSON AND JOHNSON,,77.0,YR,E,F,Y,,,20210630.0,,MD,JP,JP,2021,Q2,Elderly
144585189,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,9,F,,20210920.0,20180130,20210930,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210930.0,,HP,CA,CA,2021,Q3,Elderly
144585189,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,9,F,,20210920.0,20180130,20210930,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210930.0,,HP,CA,CA,2021,Q3,Elderly
144585189,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,9,F,,20210920.0,20180130,20210930,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210930.0,,HP,CA,CA,2021,Q3,Elderly
144585189,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,9,F,,20210920.0,20180130,20210930,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210930.0,,HP,CA,CA,2021,Q3,Elderly
144585189,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,9,F,,20210920.0,20180130,20210930,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20210930.0,,HP,CA,CA,2021,Q3,Elderly
162879193,16287919,78,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Acute kidney injury,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,78,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Chronic kidney disease,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,78,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,End stage renal disease,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,78,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Nephrogenic anaemia,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
162879193,16287919,78,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Renal failure,,2021,Q3,3,F,20090914.0,20210713.0,20190508,20210721,EXP,,US-ASTRAZENECA-2019SE63186,ASTRAZENECA,,15651.0,DY,,F,Y,100.7,KG,20210721.0,,,US,US,2021,Q3,Elderly
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Arthralgia,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Bronchitis,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Constipation,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Cough,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Dyspnoea,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Ear disorder,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Ear infection,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Eyelid infection,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Heart rate increased,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Hepatic cirrhosis,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Hepatic steatosis,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Influenza,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Localised infection,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Malaise,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Musculoskeletal pain,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Neck pain,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Neuralgia,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Pain in extremity,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Paranasal cyst,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Polyp,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Sinusitis,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Therapeutic response shortened,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Tinnitus,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Tympanic membrane perforation,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Viral infection,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
172368292,17236829,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q3,Weight increased,,2021,Q3,2,F,,20210726.0,20200106,20210805,EXP,,CA-PFIZER INC-2019561414,PFIZER,,60.0,YR,,F,Y,120.0,KG,20210805.0,,HP,CA,CA,2021,Q3,Adult
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Drug interaction,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Drug level above therapeutic,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Drug level increased,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Drug-induced liver injury,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Gait disturbance,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Hepatocellular injury,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Laboratory test abnormal,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Muscle disorder,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
181569284,18156928,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,100.0,MG,,,2021,Q3,Rhabdomyolysis,,2021,Q3,4,F,,20210807.0,20200817,20210818,EXP,,CA-ACCORD-195666,ACCORD,,76.0,YR,,F,Y,,,20210818.0,,HP,CA,CA,2021,Q3,Elderly
182176014,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Dizziness,,2021,Q3,4,F,20200515.0,20210907.0,20200901,20210917,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210917.0,,HP,JP,JP,2021,Q3,Adult
182176014,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Dyshidrotic eczema,,2021,Q3,4,F,20200515.0,20210907.0,20200901,20210917,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210917.0,,HP,JP,JP,2021,Q3,Adult
182176014,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Enteritis infectious,,2021,Q3,4,F,20200515.0,20210907.0,20200901,20210917,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210917.0,,HP,JP,JP,2021,Q3,Adult
182176014,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Erythema multiforme,,2021,Q3,4,F,20200515.0,20210907.0,20200901,20210917,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210917.0,,HP,JP,JP,2021,Q3,Adult
182176014,18217601,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",200.0,MG,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Nasopharyngitis,,2021,Q3,4,F,20200515.0,20210907.0,20200901,20210917,EXP,,JP-JNJFOC-20200844855,JOHNSON AND JOHNSON,,48.0,YR,A,M,Y,,,20210917.0,,HP,JP,JP,2021,Q3,Adult
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Drug interaction,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Drug-induced liver injury,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Hepatocellular injury,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Musculoskeletal toxicity,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Rhabdomyolysis,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
182236162,18223616,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, QD",,,Y,, UNKNOWN,,,100.0,MG,,QD,2021,Q3,Toxicity to various agents,,2021,Q3,2,F,,20210728.0,20200902,20210806,EXP,,CA-LUPIN PHARMACEUTICALS INC.-2020-05244,LUPIN,,76.0,YR,,F,Y,,,20210806.0,,CN,NL,CA,2021,Q3,Elderly
185109153,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Brain stem infarction,,2021,Q3,3,F,20200814.0,20210712.0,20201117,20210724,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20210724.0,,MD,JP,JP,2021,Q3,Elderly
185109153,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,3,F,20200814.0,20210712.0,20201117,20210724,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20210724.0,,MD,JP,JP,2021,Q3,Elderly
185109153,18510915,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Myocardial infarction,,2021,Q3,3,F,20200814.0,20210712.0,20201117,20210724,EXP,,JP-JNJFOC-20201031214,JOHNSON AND JOHNSON,,68.0,YR,E,M,Y,,,20210724.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Off label use,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Pulmonary artery thrombosis,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,Y,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Venous thrombosis limb,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,U,,,204042.0,,,,,2021,Q3,Off label use,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,U,,,204042.0,,,,,2021,Q3,Pulmonary artery thrombosis,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
189082264,18908226,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,U,,,204042.0,,,,,2021,Q3,Venous thrombosis limb,,2021,Q3,4,F,20190204.0,20210716.0,20210218,20210723,EXP,,JP-JNJFOC-20210230296,JOHNSON AND JOHNSON,"KENJI DAN, MEGUMI KINOSHITA. O?009 A CASE OF DIABETIC PATIENT WITH CARCINOMA WHO DEVELOPED PULMONARY THROMBOSIS AND DEEP VEIN THROMBOSIS AFTER ADMINISTRATION OF SGLT2 INHIBITORS. THE 58TH KANTO KOSHINETSU MEETING OF THE JAPAN DIABETES SOCIETY [HELD ON AIR/ONLINE]. 2021.1.30,31?63",67.0,YR,E,M,Y,,,20210723.0,,MD,JP,JP,2021,Q3,Elderly
1901242910,19012429,7,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,10,F,,20210819.0,20210315,20210913,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20210913.0,,CN,CA,CA,2021,Q3,Elderly
1901242910,19012429,7,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,10,F,,20210819.0,20210315,20210913,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20210913.0,,CN,CA,CA,2021,Q3,Elderly
1901242910,19012429,7,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,10,F,,20210819.0,20210315,20210913,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20210913.0,,CN,CA,CA,2021,Q3,Elderly
1901242910,19012429,7,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,10,F,,20210819.0,20210315,20210913,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20210913.0,,CN,CA,CA,2021,Q3,Elderly
1901242910,19012429,7,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,10,F,,20210819.0,20210315,20210913,EXP,,CA-TAKEDA-2021TJP006850,TAKEDA,,76.0,YR,,F,Y,,,20210913.0,,CN,CA,CA,2021,Q3,Elderly
1902563512,19025635,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,12,F,,20210922.0,20210318,20210929,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20210929.0,,MD,CA,CA,2021,Q3,Elderly
1902563512,19025635,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,12,F,,20210922.0,20210318,20210929,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20210929.0,,MD,CA,CA,2021,Q3,Elderly
1902563512,19025635,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,12,F,,20210922.0,20210318,20210929,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20210929.0,,MD,CA,CA,2021,Q3,Elderly
1902563512,19025635,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,12,F,,20210922.0,20210318,20210929,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20210929.0,,MD,CA,CA,2021,Q3,Elderly
1902563512,19025635,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,12,F,,20210922.0,20210318,20210929,EXP,,CA-PFIZER INC-2021284310,PFIZER,,76.0,YR,,F,Y,,,20210929.0,,MD,CA,CA,2021,Q3,Elderly
192394834,19239483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, 2X/DAY",,,,,,,,300.0,MG,,BID,2021,Q3,Carpal tunnel syndrome,,2021,Q3,4,F,,20210712.0,20210510,20210727,EXP,,CA-PFIZER INC-2021502921,PFIZER,,73.0,YR,,M,Y,,,20210727.0,,CN,CA,CA,2021,Q3,Elderly
192394834,19239483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, 2X/DAY",,,,,,,,300.0,MG,,BID,2021,Q3,Condition aggravated,,2021,Q3,4,F,,20210712.0,20210510,20210727,EXP,,CA-PFIZER INC-2021502921,PFIZER,,73.0,YR,,M,Y,,,20210727.0,,CN,CA,CA,2021,Q3,Elderly
192394834,19239483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, 2X/DAY",,,,,,,,300.0,MG,,BID,2021,Q3,Drug ineffective,,2021,Q3,4,F,,20210712.0,20210510,20210727,EXP,,CA-PFIZER INC-2021502921,PFIZER,,73.0,YR,,M,Y,,,20210727.0,,CN,CA,CA,2021,Q3,Elderly
192909562,19290956,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,U,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Bladder cancer,,2021,Q3,2,F,20200317.0,20210702.0,20210523,20210709,EXP,,JP-JNJFOC-20210537289,JOHNSON AND JOHNSON,,50.0,YR,A,M,Y,,,20210709.0,,MD,JP,JP,2021,Q3,Adult
194764982,19476498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,204042.0,,,TABLET,,2021,Q3,Retinal haemorrhage,,2021,Q3,2,F,201705.0,20210706.0,20210630,20210715,EXP,,JP-JNJFOC-20210666055,JOHNSON AND JOHNSON,,43.0,YR,A,F,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Adult
194766583,19476658,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,,,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Pancreatic carcinoma,,2021,Q3,3,F,201805.0,20210825.0,20210630,20210903,EXP,,JP-JNJFOC-20210666252,JOHNSON AND JOHNSON,,77.0,YR,E,F,Y,,,20210903.0,,MD,JP,JP,2021,Q3,Elderly
194825802,19482580,4,C,CANAGLIFLOZIN/TENELIGLIPTIN,,2,Oral,DOSE UNKNOWN,,,,,,,,,,TABLET,,2021,Q3,Cardiac failure,Cardiac failure,2021,Q3,2,F,,20210621.0,20210701,20210702,EXP,,JP-ALVOGEN-2021-ALVOGEN-117141,ALVOGEN,,88.0,YR,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Elderly
194825802,19482580,4,C,CANAGLIFLOZIN/TENELIGLIPTIN,,2,Oral,DOSE UNKNOWN,,,,,,,,,,TABLET,,2021,Q3,Chronic kidney disease,Chronic kidney disease,2021,Q3,2,F,,20210621.0,20210701,20210702,EXP,,JP-ALVOGEN-2021-ALVOGEN-117141,ALVOGEN,,88.0,YR,,M,Y,,,20210702.0,,MD,JP,JP,2021,Q3,Elderly
194865721,19486572,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY; PREFERABLY BEFORE BREAKFAST,244.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Blood potassium decreased,,2021,Q3,1,I,20210622.0,20210624.0,20210702,20210702,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-TEVA-2021-GB-1927604,TEVA,,66.0,YR,E,F,Y,64.0,KG,20210702.0,,PH,GB,GB,2021,Q3,Elderly
194865721,19486572,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY; PREFERABLY BEFORE BREAKFAST,244.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Hypokalaemia,,2021,Q3,1,I,20210622.0,20210624.0,20210702,20210702,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-TEVA-2021-GB-1927604,TEVA,,66.0,YR,E,F,Y,64.0,KG,20210702.0,,PH,GB,GB,2021,Q3,Elderly
194865721,19486572,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY; PREFERABLY BEFORE BREAKFAST,244.0,DF,,,,,,1.0,DF,,QD,2021,Q3,Palpitations,,2021,Q3,1,I,20210622.0,20210624.0,20210702,20210702,EXP,GB-MHRA-TPP47893256C7535909YC1624369449886,GB-TEVA-2021-GB-1927604,TEVA,,66.0,YR,E,F,Y,64.0,KG,20210702.0,,PH,GB,GB,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Chest pain,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Disorientation,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Ear pruritus,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Intentional product use issue,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Malaise,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Myocardial infarction,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Off label use,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194972241,19497224,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,300.0,MG,,,2021,Q3,Throat irritation,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861324,ROCHE,,67.0,YR,,F,Y,,,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Arthralgia,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Blood pressure diastolic abnormal,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Blood pressure diastolic decreased,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Blood pressure fluctuation,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Blood pressure increased,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Breast disorder,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Contusion,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Cystitis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Fibromyalgia,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Finger deformity,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Heart rate increased,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Hypertension,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Hypotension,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Hypothyroidism,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Intentional product use issue,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Intercepted medication error,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Kidney infection,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Lower respiratory tract infection,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Nasopharyngitis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Nodule,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Oxygen saturation decreased,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Pain,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Steroid diabetes,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Urinary tract infection,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Vascular stenosis,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194978041,19497804,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2021,Q3,Weight decreased,,2021,Q3,1,I,,20210630.0,20210706,20210706,EXP,,CA-ROCHE-2861264,ROCHE,,67.0,YR,,F,Y,69.0,KG,20210706.0,,HP,CA,CA,2021,Q3,Elderly
194999971,19499997,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,(PLEASE HAVE A BLOOD TEST TO CHE...,578.958,DF,,,,,,,,,,2021,Q3,Acute kidney injury,,2021,Q3,1,I,20210623.0,20210625.0,20210707,20210707,EXP,GB-MHRA-TPP23730756C2552407YC1624447752958,GB-NOVOPROD-824698,NOVO NORDISK,,69.0,YR,,F,Y,93.0,KG,20210707.0,,HP,GB,GB,2021,Q3,Elderly
194999971,19499997,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,(PLEASE HAVE A BLOOD TEST TO CHE...,578.958,DF,,,,,,,,,,2021,Q3,Diarrhoea,,2021,Q3,1,I,20210623.0,20210625.0,20210707,20210707,EXP,GB-MHRA-TPP23730756C2552407YC1624447752958,GB-NOVOPROD-824698,NOVO NORDISK,,69.0,YR,,F,Y,93.0,KG,20210707.0,,HP,GB,GB,2021,Q3,Elderly
194999971,19499997,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,(PLEASE HAVE A BLOOD TEST TO CHE...,578.958,DF,,,,,,,,,,2021,Q3,Drug half-life increased,,2021,Q3,1,I,20210623.0,20210625.0,20210707,20210707,EXP,GB-MHRA-TPP23730756C2552407YC1624447752958,GB-NOVOPROD-824698,NOVO NORDISK,,69.0,YR,,F,Y,93.0,KG,20210707.0,,HP,GB,GB,2021,Q3,Elderly
194999971,19499997,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,(PLEASE HAVE A BLOOD TEST TO CHE...,578.958,DF,,,,,,,,,,2021,Q3,Hypertension,,2021,Q3,1,I,20210623.0,20210625.0,20210707,20210707,EXP,GB-MHRA-TPP23730756C2552407YC1624447752958,GB-NOVOPROD-824698,NOVO NORDISK,,69.0,YR,,F,Y,93.0,KG,20210707.0,,HP,GB,GB,2021,Q3,Elderly
194999971,19499997,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,(PLEASE HAVE A BLOOD TEST TO CHE...,578.958,DF,,,,,,,,,,2021,Q3,Illness,,2021,Q3,1,I,20210623.0,20210625.0,20210707,20210707,EXP,GB-MHRA-TPP23730756C2552407YC1624447752958,GB-NOVOPROD-824698,NOVO NORDISK,,69.0,YR,,F,Y,93.0,KG,20210707.0,,HP,GB,GB,2021,Q3,Elderly
195101721,19510172,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,D,,,,,,,,,2021,Q3,Myocarditis,,2021,Q3,1,I,,20210616.0,20210709,20210709,EXP,,CA-APOTEX-2021AP014893,APOTEX,,61.0,YR,,M,Y,,,20210709.0,,CN,CA,CA,2021,Q3,Adult
195209611,19520961,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,ONE TABLET AM DAILY,,,,,,,,,,TABLET,QD,2021,Q3,Dizziness,,2021,Q3,1,I,20210623.0,20210706.0,20210712,20210712,EXP,GB-MHRA-TPP40088065C5468367YC1625499123244,GB-JNJFOC-20210713101,JOHNSON AND JOHNSON,,55.0,YR,A,F,Y,99.0,KG,20210712.0,,HP,GB,GB,2021,Q3,Adult
195209611,19520961,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,ONE TABLET AM DAILY,,,,,,,,,,TABLET,QD,2021,Q3,Fatigue,,2021,Q3,1,I,20210623.0,20210706.0,20210712,20210712,EXP,GB-MHRA-TPP40088065C5468367YC1625499123244,GB-JNJFOC-20210713101,JOHNSON AND JOHNSON,,55.0,YR,A,F,Y,99.0,KG,20210712.0,,HP,GB,GB,2021,Q3,Adult
195312361,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195312361,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195312361,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195312361,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195312361,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195363952,19536395,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195363952,19536395,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,2,F,,20210809.0,20210713,20210817,EXP,,CA-BAUSCH-BL-2021-024372,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,HP,CA,CA,2021,Q3,Elderly
195388481,19538848,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195388481,19538848,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195388481,19538848,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195388481,19538848,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195388481,19538848,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024333,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,CN,CA,CA,2021,Q3,Elderly
195412621,19541262,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024357,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,HP,CA,CA,2021,Q3,Elderly
195412621,19541262,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024357,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,HP,CA,CA,2021,Q3,Elderly
195412621,19541262,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024357,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,HP,CA,CA,2021,Q3,Elderly
195412621,19541262,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024357,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,HP,CA,CA,2021,Q3,Elderly
195412621,19541262,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210705.0,20210713,20210713,EXP,,CA-BAUSCH-BL-2021-024357,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210713.0,,HP,CA,CA,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Atrial fibrillation,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Cardiac failure chronic,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Diabetes mellitus,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Ejection fraction decreased,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Fatigue,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Oedema,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Ventricular hypokinesia,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195518651,19551865,5,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,100 MG,,,U,,,,,100.0,MG,,,2021,Q3,Ventricular remodelling,,2021,Q3,1,I,,20210706.0,20210715,20210715,EXP,,NVSJ2021JP010736,NOVARTIS,,66.0,YR,,M,Y,,,20210715.0,,MD,JP,JP,2021,Q3,Elderly
195529511,19552951,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM DAILY; PREFERABLY BEFORE BREAKFAST,,,,,,,,300.0,MG,TABLET,QD,2021,Q3,Gastrointestinal haemorrhage,,2021,Q3,1,I,,20210708.0,20210715,20210715,EXP,GB-MHRA-MIDB-BC8D4190-EB5E-47AD-98C3-B063CD8A3A6D,GB-TEVA-2021-GB-1932159,TEVA,,67.0,YR,E,F,Y,,,20210715.0,,PH,GB,GB,2021,Q3,Elderly
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Arthralgia,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Drug intolerance,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Fatigue,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Flank pain,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Flushing,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Gastrointestinal disorder,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Headache,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Libido decreased,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Nausea,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195757692,19575769,3,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,UNKNOWN,,2021,Q3,Pruritus,,2021,Q3,2,F,2021.0,20210714.0,20210719,20210721,PER,,US-BIOGEN-2021BI01024313,BIOGEN,,56.0,YR,,M,Y,,,20210721.0,,CN,US,US,2021,Q3,Adult
195824241,19582424,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,1,I,,20210712.0,20210719,20210719,EXP,,CA-ASTRAZENECA-2021A621344,ASTRAZENECA,,76.0,YR,,F,Y,,,20210720.0,,MD,CA,CA,2021,Q3,Elderly
195824241,19582424,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210712.0,20210719,20210719,EXP,,CA-ASTRAZENECA-2021A621344,ASTRAZENECA,,76.0,YR,,F,Y,,,20210720.0,,MD,CA,CA,2021,Q3,Elderly
195824241,19582424,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210712.0,20210719,20210719,EXP,,CA-ASTRAZENECA-2021A621344,ASTRAZENECA,,76.0,YR,,F,Y,,,20210720.0,,MD,CA,CA,2021,Q3,Elderly
195824241,19582424,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210712.0,20210719,20210719,EXP,,CA-ASTRAZENECA-2021A621344,ASTRAZENECA,,76.0,YR,,F,Y,,,20210720.0,,MD,CA,CA,2021,Q3,Elderly
195824241,19582424,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210712.0,20210719,20210719,EXP,,CA-ASTRAZENECA-2021A621344,ASTRAZENECA,,76.0,YR,,F,Y,,,20210720.0,,MD,CA,CA,2021,Q3,Elderly
195920921,19592092,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q3,Jaundice cholestatic,,2021,Q3,1,I,,20210707.0,20210722,20210722,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-305168,RANBAXY,,64.0,YR,,M,Y,,,20210722.0,,HP,GB,GB,2021,Q3,Adult
196253571,19625357,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Anticoagulation drug level above therapeutic,,2021,Q3,1,I,,20210718.0,20210729,20210729,EXP,,US-ACCORD-233459,ACCORD,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021 JUN 7?13(6):E15506",71.0,YR,E,M,Y,,,20210729.0,,HP,US,US,2021,Q3,Elderly
196253571,19625357,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210718.0,20210729,20210729,EXP,,US-ACCORD-233459,ACCORD,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021 JUN 7?13(6):E15506",71.0,YR,E,M,Y,,,20210729.0,,HP,US,US,2021,Q3,Elderly
196253571,19625357,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210718.0,20210729,20210729,EXP,,US-ACCORD-233459,ACCORD,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021 JUN 7?13(6):E15506",71.0,YR,E,M,Y,,,20210729.0,,HP,US,US,2021,Q3,Elderly
196253571,19625357,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,Y,,,,,,,,,2021,Q3,Orthostatic hypotension,,2021,Q3,1,I,,20210718.0,20210729,20210729,EXP,,US-ACCORD-233459,ACCORD,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021 JUN 7?13(6):E15506",71.0,YR,E,M,Y,,,20210729.0,,HP,US,US,2021,Q3,Elderly
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Anxiety,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Asthenia,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Eye disorder,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Hypoaesthesia,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Mobility decreased,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Neuralgia,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Pain,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Psychogenic seizure,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Tic,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196293421,19629342,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, DAILY",,,,,,,,100.0,MG,,QD,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,202007.0,20210714.0,20210729,20210729,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202107011961,ELI LILLY AND CO,,40.0,YR,,M,Y,,,20210729.0,,CN,CA,CA,2021,Q3,Adult
196443971,19644397,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,,20210721.0,20210801,20210801,EXP,,JP-JNJFOC-20210763676,JOHNSON AND JOHNSON,,7.0,DEC,E,M,Y,,,20210802.0,,MD,JP,JP,2021,Q3,Child
196443971,19644397,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, QD",,,U,,,,204042.0,100.0,MG,TABLET,QD,2021,Q3,COVID-19,,2021,Q3,1,I,,20210721.0,20210801,20210801,EXP,,JP-JNJFOC-20210763676,JOHNSON AND JOHNSON,,7.0,DEC,E,M,Y,,,20210802.0,,MD,JP,JP,2021,Q3,Child
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Alanine aminotransferase increased,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Aspartate aminotransferase increased,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Dyspnoea,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Hypoventilation,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Interstitial lung disease,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Joint swelling,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Limb mass,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Off label use,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Peripheral swelling,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Product use in unapproved indication,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Rash pruritic,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Raynaud's phenomenon,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196514831,19651483,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,1 EVERY 1 DAYS,,,,,,,,300.0,ML,,,2021,Q3,Weight increased,,2021,Q3,1,I,,20210723.0,20210803,20210803,EXP,CA-MHPD-E2B_03370802,CA-ACCORD-234141,ACCORD,,48.0,YR,,M,Y,,,20210803.0,,HP,CA,CA,2021,Q3,Adult
196536251,19653625,3,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,"UNK, QD",,,U,,,,,,,,QD,2021,Q3,Acute kidney injury,,2021,Q3,1,I,2013.0,20210726.0,20210803,20210803,EXP,,ES-SA-2021SA252761,SANOFI AVENTIS,,49.0,YR,A,M,Y,77.0,KG,20210803.0,,CN,ES,ES,2021,Q3,Adult
196536251,19653625,3,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,"UNK, QD",,,U,,,,,,,,QD,2021,Q3,Cerebrovascular accident,,2021,Q3,1,I,2013.0,20210726.0,20210803,20210803,EXP,,ES-SA-2021SA252761,SANOFI AVENTIS,,49.0,YR,A,M,Y,77.0,KG,20210803.0,,CN,ES,ES,2021,Q3,Adult
196536251,19653625,3,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,"UNK, QD",,,U,,,,,,,,QD,2021,Q3,Memory impairment,,2021,Q3,1,I,2013.0,20210726.0,20210803,20210803,EXP,,ES-SA-2021SA252761,SANOFI AVENTIS,,49.0,YR,A,M,Y,77.0,KG,20210803.0,,CN,ES,ES,2021,Q3,Adult
196536251,19653625,3,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,"UNK, QD",,,U,,,,,,,,QD,2021,Q3,Myocardial infarction,,2021,Q3,1,I,2013.0,20210726.0,20210803,20210803,EXP,,ES-SA-2021SA252761,SANOFI AVENTIS,,49.0,YR,A,M,Y,77.0,KG,20210803.0,,CN,ES,ES,2021,Q3,Adult
196536251,19653625,3,C,VOKANAMET [CANAGLIFLOZIN HEMIHYDRATE;METFORMIN HYDROCHLORIDE],,2,Unknown,"UNK, QD",,,U,,,,,,,,QD,2021,Q3,Poor peripheral circulation,,2021,Q3,1,I,2013.0,20210726.0,20210803,20210803,EXP,,ES-SA-2021SA252761,SANOFI AVENTIS,,49.0,YR,A,M,Y,77.0,KG,20210803.0,,CN,ES,ES,2021,Q3,Adult
196540971,19654097,2,C,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Diabetic ketoacidosis,,2021,Q3,1,I,,20210727.0,20210804,20210804,EXP,,JP-ASTRAZENECA-2021A650111,ASTRAZENECA,"OHTA M, ET AL.. 113 A CASE OF DIABETIC KETOACIDOSIS WITH MARKED ABNORMAL LIPIDS AND PSEUDOHYPONATRAEMIA ON ADMISSION.. THE 244TH TOKAI REGINAL MEETING OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE? 2021 JUN 27?? 2021?",35.0,YR,,F,Y,,,20210804.0,,MD,JP,JP,2021,Q3,Adult
196540971,19654097,2,C,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Lipids abnormal,,2021,Q3,1,I,,20210727.0,20210804,20210804,EXP,,JP-ASTRAZENECA-2021A650111,ASTRAZENECA,"OHTA M, ET AL.. 113 A CASE OF DIABETIC KETOACIDOSIS WITH MARKED ABNORMAL LIPIDS AND PSEUDOHYPONATRAEMIA ON ADMISSION.. THE 244TH TOKAI REGINAL MEETING OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE? 2021 JUN 27?? 2021?",35.0,YR,,F,Y,,,20210804.0,,MD,JP,JP,2021,Q3,Adult
196540971,19654097,2,C,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Unknown,DOSE UNKNOWN,,,,,,,,,,,,2021,Q3,Pseudohyponatraemia,,2021,Q3,1,I,,20210727.0,20210804,20210804,EXP,,JP-ASTRAZENECA-2021A650111,ASTRAZENECA,"OHTA M, ET AL.. 113 A CASE OF DIABETIC KETOACIDOSIS WITH MARKED ABNORMAL LIPIDS AND PSEUDOHYPONATRAEMIA ON ADMISSION.. THE 244TH TOKAI REGINAL MEETING OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE? 2021 JUN 27?? 2021?",35.0,YR,,F,Y,,,20210804.0,,MD,JP,JP,2021,Q3,Adult
196916901,19691690,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,204042.0,300.0,MG,TABLET,,2021,Q3,Ketoacidosis,,2021,Q3,1,I,,20210803.0,20210812,20210812,EXP,,US-JNJFOC-20210813250,JOHNSON AND JOHNSON,"AMIANDA E.A., GAVIGAN T.S., TALISHINSKIY T., EWING D.R., SCHMIDT H.J.,  TWO CASES OF EUGLYCEMIC DIABETIC KETOACIDOSIS AFTER BARIATRIC SURGERY ASSOCIATED WITH SODIUM?GLUCOSE COTRANSPORTER?2 INHIBITOR USE OBESITYSURGERY 2021 31 3848?3850",47.0,YR,A,F,Y,,,20210812.0,,HP,US,US,2021,Q3,Adult
196986371,19698637,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, QD",,,,, UNKNOWN,,,,,,QD,2021,Q3,Nausea,,2021,Q3,1,I,20210113.0,20210422.0,20210813,20210813,EXP,GB-MHRA-ADR 24822822,GB-ALKEM LABORATORIES LIMITED-GB-ALKEM-2021-02517,ALKEM,,57.0,YR,,M,Y,80.0,KG,20210813.0,,HP,GB,GB,2021,Q3,Adult
196987763,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q3,Accidental overdose,,2021,Q3,3,F,,20210819.0,20210813,20210827,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,1.0,YR,I,F,Y,,,20210827.0,,MD,JP,JP,2021,Q3,Child
196987763,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q3,Lactic acidosis,,2021,Q3,3,F,,20210819.0,20210813,20210827,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,1.0,YR,I,F,Y,,,20210827.0,,MD,JP,JP,2021,Q3,Child
196987763,19698776,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,,,TABLET,,2021,Q3,Urine output increased,,2021,Q3,3,F,,20210819.0,20210813,20210827,EXP,,JP-JNJFOC-20210825733,JOHNSON AND JOHNSON,,1.0,YR,I,F,Y,,,20210827.0,,MD,JP,JP,2021,Q3,Child
197107571,19710757,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027585,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107571,19710757,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027585,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107571,19710757,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027585,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107571,19710757,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027585,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107571,19710757,13,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027585,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107651,19710765,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107651,19710765,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107651,19710765,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107651,19710765,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197107651,19710765,6,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210809.0,20210817,20210817,EXP,,CA-BAUSCH-BL-2021-027586,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20210817.0,,CN,CA,CA,2021,Q3,Elderly
197138762,19713876,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q3,Abscess,,2021,Q3,2,F,20200701.0,20210812.0,20210818,20210823,EXP,,JP-ABBVIE-20K-087-3480296-00,ABBVIE,,39.0,YR,,M,Y,116.0,KG,20210823.0,,MD,JP,JP,2021,Q3,Adult
197138762,19713876,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q3,Drug ineffective,,2021,Q3,2,F,20200701.0,20210812.0,20210818,20210823,EXP,,JP-ABBVIE-20K-087-3480296-00,ABBVIE,,39.0,YR,,M,Y,116.0,KG,20210823.0,,MD,JP,JP,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Arteriosclerosis coronary artery,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Blood cholesterol abnormal,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Cardiac arrest,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Chronic obstructive pulmonary disease,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Diabetes mellitus,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Glycosylated haemoglobin increased,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,HIV infection,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Hypertension,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197199331,19719933,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Myocardial ischaemia,,2021,Q3,1,I,20200206.0,20210812.0,20210818,20210818,EXP,,GB-009507513-2108GBR004055,MERCK,,50.0,YR,,M,Y,89.0,KG,20210818.0,,PH,GB,GB,2021,Q3,Adult
197273262,19727326,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, QD",,,,,,,,300.0,MG,,QD,2021,Q3,Back pain,,2021,Q3,2,F,20210728.0,20210917.0,20210820,20210924,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20210924.0,,MD,ES,ES,2021,Q3,Elderly
197754621,19775462,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,1,I,,20210824.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947201,TEVA,,76.0,YR,E,F,Y,,,20210901.0,,MD,CA,CA,2021,Q3,Elderly
197754621,19775462,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210824.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947201,TEVA,,76.0,YR,E,F,Y,,,20210901.0,,MD,CA,CA,2021,Q3,Elderly
197754621,19775462,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210824.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947201,TEVA,,76.0,YR,E,F,Y,,,20210901.0,,MD,CA,CA,2021,Q3,Elderly
197754621,19775462,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210824.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947201,TEVA,,76.0,YR,E,F,Y,,,20210901.0,,MD,CA,CA,2021,Q3,Elderly
197754621,19775462,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210824.0,20210901,20210901,EXP,,CA-TEVA-2021-CA-1947201,TEVA,,76.0,YR,E,F,Y,,,20210901.0,,MD,CA,CA,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Anticoagulation drug level above therapeutic,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Anticoagulation drug level below therapeutic,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Asthenia,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Cardiac murmur,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Cardiorenal syndrome,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Drug interaction,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Dry mouth,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Dysstasia,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Fall,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Hypovolaemia,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Orthostatic hypotension,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
197852711,19785271,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2021,Q3,Polyuria,,2021,Q3,1,I,,20210720.0,20210903,20210903,EXP,,US-GLAXOSMITHKLINE-US2021GSK171860,GLAXOSMITHKLINE,"BECERRA AF, BOCH M, AL?MEZRAKCHI YA. ROPINIROLE?ASSOCIATED ORTHOSTATIC HYPOTENSION AS CAUSE OF A PRESCRIBING CASCADE IN AN ELDERLY MAN. CUREUS. 2021?13 (6)",71.0,YR,,M,Y,,,20210903.0,,MD,US,US,2021,Q3,Elderly
198118062,19811806,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q3,Infusion related reaction,,2021,Q3,2,F,20210831.0,20210910.0,20210909,20210916,EXP,,GB-ROCHE-2905434,ROCHE,,65.0,YR,,M,Y,69.7,KG,20210916.0,,MD,GB,GB,2021,Q3,Elderly
198124461,19812446,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949560,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,HP,CA,CA,2021,Q3,Elderly
198124461,19812446,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949560,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,HP,CA,CA,2021,Q3,Elderly
198124461,19812446,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949560,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,HP,CA,CA,2021,Q3,Elderly
198124461,19812446,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949560,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,HP,CA,CA,2021,Q3,Elderly
198124461,19812446,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949560,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,HP,CA,CA,2021,Q3,Elderly
198134061,19813406,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,16,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Asthma,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198134061,19813406,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949562,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,MD,CA,CA,2021,Q3,Elderly
198157981,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Asthma,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,CN,CA,CA,2021,Q3,Elderly
198157981,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Blood count abnormal,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,CN,CA,CA,2021,Q3,Elderly
198157981,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Gastrooesophageal reflux disease,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,CN,CA,CA,2021,Q3,Elderly
198157981,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Hyperglycaemia,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,CN,CA,CA,2021,Q3,Elderly
198157981,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,TABLET,,2021,Q3,Type 2 diabetes mellitus,,2021,Q3,1,I,,20210831.0,20210910,20210910,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20210910.0,,CN,CA,CA,2021,Q3,Elderly
198237481,19823748,1,PS,CANAGLIFLOZIN/METFORMIN,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,2 TABLETS 150/1000 MG,,,U,,,,205879.0,,,PROLONGED-RELEASE TABLET,,2021,Q3,Ketoacidosis,,2021,Q3,1,I,,20210907.0,20210913,20210913,EXP,CH-SM-2021-21568,CH-JNJFOC-20210911213,JOHNSON AND JOHNSON,,57.0,YR,A,F,Y,,,20210913.0,,PH,CH,CH,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Blood glucose decreased,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Confusional state,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Hyperhidrosis,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Nausea,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,1.0,DF,TABLET,QD,2021,Q3,Palpitations,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Blood glucose decreased,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Confusional state,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Hyperhidrosis,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Nausea,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198403201,19840320,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,, UNKNOWN,,,0.5,DF,TABLET,QD,2021,Q3,Palpitations,,2021,Q3,1,I,202108.0,20210823.0,20210915,20210915,EXP,,CN-ASTRAZENECA-2021A701875,ASTRAZENECA,,49.0,YR,,M,Y,64.0,KG,20210915.0,,CN,CN,CN,2021,Q3,Adult
198437111,19843711,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ML, DAILY",,,U,,,,,100.0,ML,,QD,2021,Q3,Blood glucose increased,,2021,Q3,1,I,20191116.0,20191118.0,20210917,20210917,PER,,US-ELI_LILLY_AND_COMPANY-US201911008599,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20210917.0,,CN,US,US,2021,Q3,Elderly
198437111,19843711,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ML, DAILY",,,U,,,,,100.0,ML,,QD,2021,Q3,Drug ineffective,,2021,Q3,1,I,20191116.0,20191118.0,20210917,20210917,PER,,US-ELI_LILLY_AND_COMPANY-US201911008599,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20210917.0,,CN,US,US,2021,Q3,Elderly
198437111,19843711,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 ML, DAILY",,,U,,,,,100.0,ML,,QD,2021,Q3,Product storage error,,2021,Q3,1,I,20191116.0,20191118.0,20210917,20210917,PER,,US-ELI_LILLY_AND_COMPANY-US201911008599,ELI LILLY AND CO,,69.0,YR,,M,Y,,,20210917.0,,CN,US,US,2021,Q3,Elderly
198548511,19854851,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100.0,MG,",,,,,,,,,,,,2021,Q3,Hypokalaemia,,2021,Q3,1,I,20210622.0,20210818.0,20210920,20210920,EXP,,GB-NOVOPROD-840040,NOVO NORDISK,,70.0,YR,,M,Y,140.0,KG,20210920.0,,MD,GB,GB,2021,Q3,Elderly
198548511,19854851,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100.0,MG,",,,,,,,,,,,,2021,Q3,Vomiting,,2021,Q3,1,I,20210622.0,20210818.0,20210920,20210920,EXP,,GB-NOVOPROD-840040,NOVO NORDISK,,70.0,YR,,M,Y,140.0,KG,20210920.0,,MD,GB,GB,2021,Q3,Elderly
198576701,19857670,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 MILLIGRAM,,,U,U,,,,100.0,MG,TABLET,,2021,Q3,Euglycaemic diabetic ketoacidosis,,2021,Q3,1,I,,20210915.0,20210920,20210920,EXP,,PT-MYLANLABS-2021M1062996,MYLAN,"MONTEIRO?SANTOS M, FERREIRA C, BRITO D, ELIAS T. EUGLICEMIC DIABETIC KETOACIDOSIS, AN EASILY MISSED DIAGNOSIS.. GALICIA CLIN. 2021?82?1:36?37",61.0,YR,,M,Y,,,20210920.0,,HP,PT,PT,2021,Q3,Adult
198879621,19887962,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Hypoglycaemia,,2021,Q3,1,I,202109.0,20210917.0,20210927,20210927,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005278,AEGERION,,16.0,YR,,F,Y,,,20210927.0,,CN,GB,US,2021,Q3,Youth
198879621,19887962,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MILLIGRAM, QD",,,,,,,,100.0,MG,,QD,2021,Q3,Migraine,,2021,Q3,1,I,202109.0,20210917.0,20210927,20210927,EXP,,US-AMRYT PHARMACEUTICALS DAC-AEGR005278,AEGERION,,16.0,YR,,F,Y,,,20210927.0,,CN,GB,US,2021,Q3,Youth
127626797,12762679,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,,,Tablet,,2021,Q4,Cerebral infarction,,2021,Q4,7,F,20160901.0,20211028.0,20160920,20211111,EXP,,JP-JNJFOC-20160916350,JOHNSON AND JOHNSON,,34.0,YR,A,F,Y,,,20211111.0,,MD,JP,JP,2021,Q4,Young Adult
1445851810,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,10,F,,20211119.0,20180130,20211126,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20211126.0,,MD,CA,CA,2021,Q4,Elderly
1445851810,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,10,F,,20211119.0,20180130,20211126,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20211126.0,,MD,CA,CA,2021,Q4,Elderly
1445851810,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,10,F,,20211119.0,20180130,20211126,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20211126.0,,MD,CA,CA,2021,Q4,Elderly
1445851810,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,10,F,,20211119.0,20180130,20211126,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20211126.0,,MD,CA,CA,2021,Q4,Elderly
1445851810,14458518,27,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,10,F,,20211119.0,20180130,20211126,EXP,,CA-APOTEX-2018AP005828,APOTEX,,76.0,YR,,F,Y,,,20211126.0,,MD,CA,CA,2021,Q4,Elderly
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Nephropathy,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal failure,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal injury,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
1472993712,14729937,29,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,12,F,20151201.0,20211222.0,20180406,20211230,EXP,,US-PFIZER INC-2018137097,PFIZER,,50.0,YR,,M,Y,,,20211230.0,,LW,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Nephropathy,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal failure,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,41,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Nephropathy,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal failure,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,42,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Nephropathy,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal failure,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,43,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Chronic kidney disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Nephropathy,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal failure,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
149021675,14902167,44,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Renal injury,,2021,Q4,5,F,20151201.0,20211223.0,20180516,20211231,EXP,,US-TAKEDA-2018TUS011043,TAKEDA,,50.0,YR,,M,Y,,,20211231.0,,CN,US,US,2021,Q4,Adult
154818752,15481875,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,20180502.0,20211013.0,20181010,20211018,PER,,US-AMGEN-USACT2018140585,AMGEN,,53.0,YR,A,M,Y,99.7,KG,20211018.0,,MD,US,US,2021,Q4,Adult
154818752,15481875,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Mental disorder,,2021,Q4,2,F,20180502.0,20211013.0,20181010,20211018,PER,,US-AMGEN-USACT2018140585,AMGEN,,53.0,YR,A,M,Y,99.7,KG,20211018.0,,MD,US,US,2021,Q4,Adult
154818752,15481875,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Pancreatitis,,2021,Q4,2,F,20180502.0,20211013.0,20181010,20211018,PER,,US-AMGEN-USACT2018140585,AMGEN,,53.0,YR,A,M,Y,99.7,KG,20211018.0,,MD,US,US,2021,Q4,Adult
154818752,15481875,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Hypertriglyceridaemia,,2021,Q4,2,F,20180502.0,20211013.0,20181010,20211018,PER,,US-AMGEN-USACT2018140585,AMGEN,,53.0,YR,A,M,Y,99.7,KG,20211018.0,,MD,US,US,2021,Q4,Adult
154818752,15481875,15,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Metabolic disorder,,2021,Q4,2,F,20180502.0,20211013.0,20181010,20211018,PER,,US-AMGEN-USACT2018140585,AMGEN,,53.0,YR,A,M,Y,99.7,KG,20211018.0,,MD,US,US,2021,Q4,Adult
162022053,16202205,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,D,,,,204042.0,,,Tablet,,2021,Q4,Death,,2021,Q4,3,F,,20190606.0,20190416,20211219,EXP,,JP-JNJFOC-20190424158,JOHNSON AND JOHNSON,,77.0,YR,E,F,Y,,,20211219.0,,MD,JP,JP,2021,Q4,Elderly
171791508,17179150,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2021,Q4,Hepatic function abnormal,,2021,Q4,8,F,20191203.0,20211018.0,20191219,20211027,PER,,JP-AMGEN-JPNSP2019200352,AMGEN,,51.0,YR,A,F,Y,,,20211027.0,,MD,JP,JP,2021,Q4,Adult
171791508,17179150,17,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,8,F,20191203.0,20211018.0,20191219,20211027,PER,,JP-AMGEN-JPNSP2019200352,AMGEN,,51.0,YR,A,F,Y,,,20211027.0,,MD,JP,JP,2021,Q4,Adult
171791508,17179150,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2021,Q4,Hepatic function abnormal,,2021,Q4,8,F,20191203.0,20211018.0,20191219,20211027,PER,,JP-AMGEN-JPNSP2019200352,AMGEN,,51.0,YR,A,F,Y,,,20211027.0,,MD,JP,JP,2021,Q4,Adult
171791508,17179150,18,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,8,F,20191203.0,20211018.0,20191219,20211027,PER,,JP-AMGEN-JPNSP2019200352,AMGEN,,51.0,YR,A,F,Y,,,20211027.0,,MD,JP,JP,2021,Q4,Adult
190262324,19026232,11,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,1 dosage form,,,,,,,,,,,,2021,Q4,Azotaemia,,2021,Q4,4,F,20210301.0,20211021.0,20210318,20211104,PER,,JP-AMGEN-JPNSP2021041762,AMGEN,,76.0,YR,E,F,Y,,,20211104.0,,PH,JP,JP,2021,Q4,Elderly
190262324,19026232,11,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,1 dosage form,,,,,,,,,,,,2021,Q4,Altered state of consciousness,,2021,Q4,4,F,20210301.0,20211021.0,20210318,20211104,PER,,JP-AMGEN-JPNSP2021041762,AMGEN,,76.0,YR,E,F,Y,,,20211104.0,,PH,JP,JP,2021,Q4,Elderly
190262324,19026232,11,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,1 dosage form,,,,,,,,,,,,2021,Q4,Dehydration,,2021,Q4,4,F,20210301.0,20211021.0,20210318,20211104,PER,,JP-AMGEN-JPNSP2021041762,AMGEN,,76.0,YR,E,F,Y,,,20211104.0,,PH,JP,JP,2021,Q4,Elderly
190262324,19026232,11,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,1 dosage form,,,,,,,,,,,,2021,Q4,Anuria,,2021,Q4,4,F,20210301.0,20211021.0,20210318,20211104,PER,,JP-AMGEN-JPNSP2021041762,AMGEN,,76.0,YR,E,F,Y,,,20211104.0,,PH,JP,JP,2021,Q4,Elderly
190262324,19026232,11,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,1 dosage form,,,,,,,,,,,,2021,Q4,Seizure,,2021,Q4,4,F,20210301.0,20211021.0,20210318,20211104,PER,,JP-AMGEN-JPNSP2021041762,AMGEN,,76.0,YR,E,F,Y,,,20211104.0,,PH,JP,JP,2021,Q4,Elderly
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Hypoacusis,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Depression,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191402622,19140262,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Wheezing,,2021,Q4,2,F,,20211208.0,20210415,20211217,EXP,,CA-APOTEX-2021AP008607,APOTEX,,51.0,YR,,F,Y,,,20211217.0,,MD,CA,CA,2021,Q4,Adult
191550323,19155032,2,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,1 dosage form,,,,,,,,,,Tablet,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,3,F,20181120.0,20211118.0,20210419,20211125,EXP,,JP-ABBVIE-21P-087-3865221-00,ABBVIE,,50.0,YR,,M,Y,75.0,KG,20211125.0,,MD,COUNTRY NOT SPECIFIED,JP,2021,Q4,Adult
192519772,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"take one daily, preferably before breakfast",,,,,,,,,,,QD,2021,Q4,Off label use,,2021,Q4,2,F,20210504.0,20211116.0,20210513,20211123,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20211123.0,,PH,GB,GB,2021,Q4,Elderly
192519772,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"take one daily, preferably before breakfast",,,,,,,,,,,QD,2021,Q4,Rash,,2021,Q4,2,F,20210504.0,20211116.0,20210513,20211123,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20211123.0,,PH,GB,GB,2021,Q4,Elderly
192519772,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"take one daily, preferably before breakfast",,,,,,,,,,,QD,2021,Q4,Glomerular filtration rate decreased,,2021,Q4,2,F,20210504.0,20211116.0,20210513,20211123,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20211123.0,,PH,GB,GB,2021,Q4,Elderly
192519772,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"take one daily, preferably before breakfast",,,,,,,,,,,QD,2021,Q4,Blister,,2021,Q4,2,F,20210504.0,20211116.0,20210513,20211123,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20211123.0,,PH,GB,GB,2021,Q4,Elderly
192519772,19251977,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"take one daily, preferably before breakfast",,,,,,,,,,,QD,2021,Q4,Product use in unapproved indication,,2021,Q4,2,F,20210504.0,20211116.0,20210513,20211123,EXP,GB-MHRA-TPP18947208C6212165YC1620126719214,GB-JNJFOC-20210511320,JOHNSON AND JOHNSON,,75.0,YR,E,F,Y,101.0,KG,20211123.0,,PH,GB,GB,2021,Q4,Elderly
193753637,19375363,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, Everyday",,,,,,,,100.0,MG,Tablet,QD,2021,Q4,Erythema,,2021,Q4,7,F,20210601.0,20211026.0,20210604,20211123,EXP,,JP-009507513-2106JPN001048,MERCK,,76.0,YR,,F,Y,51.0,KG,20211123.0,,MD,JP,JP,2021,Q4,Elderly
193753637,19375363,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, Everyday",,,,,,,,100.0,MG,Tablet,QD,2021,Q4,Pruritus,,2021,Q4,7,F,20210601.0,20211026.0,20210604,20211123,EXP,,JP-009507513-2106JPN001048,MERCK,,76.0,YR,,F,Y,51.0,KG,20211123.0,,MD,JP,JP,2021,Q4,Elderly
193753637,19375363,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, Everyday",,,,,,,,100.0,MG,Tablet,QD,2021,Q4,Anaphylactic shock,,2021,Q4,7,F,20210601.0,20211026.0,20210604,20211123,EXP,,JP-009507513-2106JPN001048,MERCK,,76.0,YR,,F,Y,51.0,KG,20211123.0,,MD,JP,JP,2021,Q4,Elderly
193753637,19375363,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 mg, Everyday",,,,,,,,100.0,MG,Tablet,QD,2021,Q4,Erythema,,2021,Q4,7,F,20210601.0,20211026.0,20210604,20211123,EXP,,JP-009507513-2106JPN001048,MERCK,,76.0,YR,,F,Y,51.0,KG,20211123.0,,MD,JP,JP,2021,Q4,Elderly
195312362,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,2,F,,20211012.0,20210713,20211026,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20211026.0,,MD,CA,CA,2021,Q4,Elderly
195312362,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,,20211012.0,20210713,20211026,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20211026.0,,MD,CA,CA,2021,Q4,Elderly
195312362,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,2,F,,20211012.0,20210713,20211026,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20211026.0,,MD,CA,CA,2021,Q4,Elderly
195312362,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,2,F,,20211012.0,20210713,20211026,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20211026.0,,MD,CA,CA,2021,Q4,Elderly
195312362,19531236,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,2,F,,20211012.0,20210713,20211026,EXP,,CA-ASTRAZENECA-2021A597610,ASTRAZENECA,,76.0,YR,,F,Y,,,20211026.0,,MD,CA,CA,2021,Q4,Elderly
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Systemic candida,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Acute kidney injury,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Liver disorder,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,C-reactive protein increased,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Myositis,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Device related infection,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Rectal ulcer,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Disseminated intravascular coagulation,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Encephalitis autoimmune,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Hypoalbuminaemia,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Pneumothorax,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Sepsis,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Pneumonia aspiration,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Hypertension,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Pneumonia,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197047705,19704770,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 milligram, qd",,,,,UNKNOWN,,,100.0,MG,Tablet,QD,2021,Q4,Pseudomonal bacteraemia,,2021,Q4,5,F,20210727.0,20211207.0,20210816,20211217,EXP,,JP-ROCHE-2888874,ROCHE,,62.0,YR,,M,Y,81.2,KG,20211217.0,,MD,JP,JP,2021,Q4,Adult
197273263,19727326,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, qd",,,,,,,,300.0,MG,,QD,2021,Q4,Back pain,,2021,Q4,3,F,20210728.0,20211008.0,20210820,20211014,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20211014.0,,MD,ES,ES,2021,Q4,Elderly
197273263,19727326,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, qd",,,,,,,,300.0,MG,,QD,2021,Q4,Back pain,,2021,Q4,3,F,20210728.0,20211008.0,20210820,20211014,EXP,,ES-GLAXOSMITHKLINE-ES2021GSK171840,GLAXOSMITHKLINE,,67.0,YR,,F,Y,88.0,KG,20211014.0,,MD,ES,ES,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Acute respiratory distress syndrome,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Abdominal abscess,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Metastases to peritoneum,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Pancreatic carcinoma stage IV,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Off label use,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
197984184,19798418,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Oral,"1 dosage form, daily",,,,,,,,,,Tablet,QD,2021,Q4,Jaundice cholestatic,,2021,Q4,4,F,20210725.0,20211217.0,20210906,20211221,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202108011688,ELI LILLY AND CO,,68.0,YR,,M,Y,51.0,KG,20211221.0,,CN,JP,JP,2021,Q4,Elderly
198157983,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,3,F,,20211119.0,20210910,20211129,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
198157983,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,3,F,,20211119.0,20210910,20211129,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
198157983,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,3,F,,20211119.0,20210910,20211129,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
198157983,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,3,F,,20211119.0,20210910,20211129,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
198157983,19815798,14,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,3,F,,20211119.0,20210910,20211129,EXP,,CA-TEVA-2021-CA-1949558,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Chills,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Pyrexia,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Large intestine perforation,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Subcutaneous emphysema,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Hypoaesthesia,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Perineal disorder,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Musculoskeletal pain,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Scrotal swelling,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Orchitis,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Fournier's gangrene,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198541032,19854103,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,Tablet,,2021,Q4,Therapy partial responder,,2021,Q4,2,F,20200205.0,20211112.0,20210920,20211117,EXP,,JP-SA-2021SA305621,SANOFI AVENTIS,Kadoriku F.. Fournier^s gangrene occurring during bevacizumab therapy for rectal cancer: A case report. The Nishinihon journal of urology. 2021;83:111-115,70.0,YR,E,M,Y,58.9,KG,20211117.0,,MD,JP,JP,2021,Q4,Elderly
198548512,19854851,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100.0,mg,",,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,2,F,20210622.0,20211210.0,20210920,20211223,EXP,,GB-NOVOPROD-840040,NOVO NORDISK,,70.0,YR,,M,Y,140.0,KG,20211223.0,,MD,GB,GB,2021,Q4,Elderly
198548512,19854851,12,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100.0,mg,",,,,,,,,,,,,2021,Q4,Hypokalaemia,,2021,Q4,2,F,20210622.0,20211210.0,20210920,20211223,EXP,,GB-NOVOPROD-840040,NOVO NORDISK,,70.0,YR,,M,Y,140.0,KG,20211223.0,,MD,GB,GB,2021,Q4,Elderly
198740502,19874050,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Pancreatitis necrotising,,2021,Q4,2,F,,20210927.0,20210923,20211004,EXP,,JP-FRESENIUS KABI-FK202110161,FRESENIUS KABI,Severe necrotizing pancreatitis immediately after non-abdominal surgery under general anesthesia with propofol. Clinical Journal of Gastroenterology. 2021 AUG 26;.,57.0,YR,,M,Y,,,20211004.0,,HP,JP,JP,2021,Q4,Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Brain herniation,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Brain death,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Diabetic ketosis,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Cerebrovascular insufficiency,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Respiratory failure,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Dizziness,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Cardiac arrest,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Dyspnoea,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Feeding disorder,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Headache,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Blood glucose increased,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Electrolyte imbalance,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Blood pressure diastolic increased,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Brain stem syndrome,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Vomiting,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Nausea,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Decreased appetite,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Gastrointestinal disorder,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Fatigue,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
198906583,19890658,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Cerebral haemorrhage,,2021,Q4,3,F,20210901.0,20210928.0,20210927,20211007,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202109007719,ELI LILLY AND CO,,29.0,YR,,F,Y,,,20211007.0,,CN,CN,CN,2021,Q4,Young Adult
199190282,19919028,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Nausea,,2021,Q4,2,F,20210901.0,20211026.0,20211005,20211029,EXP,,NVSJ2021JP014681,NOVARTIS,,45.0,YR,,F,Y,,,20211029.0,,MD,JP,JP,2021,Q4,Adult
199190282,19919028,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Decreased appetite,,2021,Q4,2,F,20210901.0,20211026.0,20211005,20211029,EXP,,NVSJ2021JP014681,NOVARTIS,,45.0,YR,,F,Y,,,20211029.0,,MD,JP,JP,2021,Q4,Adult
199190282,19919028,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,2,F,20210901.0,20211026.0,20211005,20211029,EXP,,NVSJ2021JP014681,NOVARTIS,,45.0,YR,,F,Y,,,20211029.0,,MD,JP,JP,2021,Q4,Adult
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Blood glucose abnormal,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Weight decreased,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Depressed mood,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Renal disorder,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Cardiac disorder,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199435641,19943564,5,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,"1 dosage form, qd",,,,,,,,,,,QD,2021,Q4,Decreased appetite,,2021,Q4,1,I,20210101.0,20211005.0,20211011,20211011,EXP,,ES-MYLANLABS-2021M1069708,MYLAN,,77.0,YR,,F,Y,66.0,KG,20211011.0,,CN,ES,ES,2021,Q4,Elderly
199621911,19962191,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2021,Q4,Hepatocellular injury,,2021,Q4,1,I,,20211006.0,20211018,20211018,EXP,,"CA-ZHEJIANG YONGTAI PHARMACEUTICALS CO..,LTD.-2120654",ZHEJIANG YONGTAI,"Juurlink.D, Brailovski E, Kim RB. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine: no pagination, 4 Aug 2020. URL: http://doi.org/10.7326/L20-0549.",76.0,YR,,F,Y,,,20211018.0,,MD,CA,CA,2021,Q4,Elderly
199621911,19962191,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2021,Q4,Toxicity to various agents,,2021,Q4,1,I,,20211006.0,20211018,20211018,EXP,,"CA-ZHEJIANG YONGTAI PHARMACEUTICALS CO..,LTD.-2120654",ZHEJIANG YONGTAI,"Juurlink.D, Brailovski E, Kim RB. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine: no pagination, 4 Aug 2020. URL: http://doi.org/10.7326/L20-0549.",76.0,YR,,F,Y,,,20211018.0,,MD,CA,CA,2021,Q4,Elderly
199621911,19962191,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2021,Q4,Drug interaction,,2021,Q4,1,I,,20211006.0,20211018,20211018,EXP,,"CA-ZHEJIANG YONGTAI PHARMACEUTICALS CO..,LTD.-2120654",ZHEJIANG YONGTAI,"Juurlink.D, Brailovski E, Kim RB. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine: no pagination, 4 Aug 2020. URL: http://doi.org/10.7326/L20-0549.",76.0,YR,,F,Y,,,20211018.0,,MD,CA,CA,2021,Q4,Elderly
199621911,19962191,2,I,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,U,,,,100.0,MG,,,2021,Q4,Rhabdomyolysis,,2021,Q4,1,I,,20211006.0,20211018,20211018,EXP,,"CA-ZHEJIANG YONGTAI PHARMACEUTICALS CO..,LTD.-2120654",ZHEJIANG YONGTAI,"Juurlink.D, Brailovski E, Kim RB. Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine: no pagination, 4 Aug 2020. URL: http://doi.org/10.7326/L20-0549.",76.0,YR,,F,Y,,,20211018.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Finger deformity,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hypertension,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hypothyroidism,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Intentional product use issue,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Intercepted medication error,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Kidney infection,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lower respiratory tract infection,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Nasopharyngitis,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Nodule,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oxygen saturation decreased,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Pain,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Rheumatoid arthritis,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Steroid diabetes,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Vascular stenosis,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Arthralgia,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure diastolic abnormal,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure diastolic decreased,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure fluctuation,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Fibromyalgia,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Fall,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Breast disorder,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Contusion,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199738261,19973826,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Cystitis,,2021,Q4,1,I,,20211012.0,20211020,20211020,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-106834,BRISTOL MYERS SQUIBB,,67.0,YR,,F,Y,69.0,KG,20211020.0,,MD,CA,CA,2021,Q4,Elderly
199762011,19976201,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,Tablet,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199762011,19976201,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,Tablet,,2021,Q4,Product use issue,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199762011,19976201,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,100.0,MG,Tablet,,2021,Q4,Off label use,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199762011,19976201,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,Tablet,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199762011,19976201,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,Tablet,,2021,Q4,Product use issue,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199762011,19976201,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,,,,204042.0,300.0,MG,Tablet,,2021,Q4,Off label use,,2021,Q4,1,I,,20211012.0,20211021,20211021,EXP,,CA-JNJFOC-20211035870,JOHNSON AND JOHNSON,,17.0,YR,T,M,Y,,,20211021.0,,MD,CA,CA,2021,Q4,Youth
199863671,19986367,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,Tablet,,2021,Q4,Fournier's gangrene,,2021,Q4,1,I,,20211013.0,20211022,20211022,EXP,,JP-JNJFOC-20211033915,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,,,20211022.0,,MD,JP,JP,2021,Q4,Adult
199940122,19994012,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,White blood cell count decreased,,2021,Q4,2,F,20210927.0,20211125.0,20211025,20211210,PER,,CN-JAZZ-2021-CN-018949,JAZZ,,66.0,YR,,F,Y,64.0,KG,20211210.0,,MD,CN,CN,2021,Q4,Elderly
199940122,19994012,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Ketoacidosis,,2021,Q4,2,F,20210927.0,20211125.0,20211025,20211210,PER,,CN-JAZZ-2021-CN-018949,JAZZ,,66.0,YR,,F,Y,64.0,KG,20211210.0,,MD,CN,CN,2021,Q4,Elderly
199940122,19994012,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2021,Q4,Neutrophil count decreased,,2021,Q4,2,F,20210927.0,20211125.0,20211025,20211210,PER,,CN-JAZZ-2021-CN-018949,JAZZ,,66.0,YR,,F,Y,64.0,KG,20211210.0,,MD,CN,CN,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Steroid diabetes,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Fibromyalgia,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Nasopharyngitis,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hypertension,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Oxygen saturation decreased,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Intercepted medication error,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Contusion,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Arthralgia,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Lower respiratory tract infection,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Cystitis,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Nodule,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Blood pressure fluctuation,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Pain,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Finger deformity,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Rheumatoid arthritis,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Vascular stenosis,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Blood pressure diastolic decreased,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Hypothyroidism,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Kidney infection,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Intentional product use issue,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Breast disorder,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Blood pressure diastolic abnormal,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
199966213,19996621,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,3,F,,20211101.0,20211025,20211104,EXP,,CA-PFIZER INC-202101407698,PFIZER,,67.0,YR,,F,Y,69.0,KG,20211104.0,,MD,CA,CA,2021,Q4,Elderly
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Fatigue,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Moraxella infection,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Liposarcoma,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Lethargy,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Renal disorder,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Headache,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Haemoglobin increased,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Product dose omission issue,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Depressed mood,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Cough,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,C-reactive protein increased,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Hydronephrosis,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Bacteraemia,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Abdominal pain,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200109031,20010903,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,U,,,,,300.0,MG,,,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,GB-002147023-NVSC2021GB090259,GB-TORRENT-00026679,TORRENT,,33.0,YR,A,M,Y,,,20211029.0,,HP,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Headache,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Product dose omission issue,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Hydronephrosis,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Renal disorder,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Lethargy,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Liposarcoma,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Moraxella infection,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Bacteraemia,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Haemoglobin increased,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Depressed mood,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,C-reactive protein increased,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200137211,20013721,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,300 Milligram Daily;,,,,,,,,300.0,MG,,QD,2021,Q4,Abdominal pain,,2021,Q4,1,I,,20211021.0,20211029,20211029,EXP,,GB-TEVA-2021-GB-1969976,TEVA,,33.0,YR,A,M,Y,,,20211029.0,,CN,GB,GB,2021,Q4,Young Adult
200141511,20014151,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211023.0,20211029,20211029,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20211029.0,,CN,CA,CA,2021,Q4,Elderly
200141511,20014151,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211023.0,20211029,20211029,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20211029.0,,CN,CA,CA,2021,Q4,Elderly
200141511,20014151,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211023.0,20211029,20211029,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20211029.0,,CN,CA,CA,2021,Q4,Elderly
200141511,20014151,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211023.0,20211029,20211029,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20211029.0,,CN,CA,CA,2021,Q4,Elderly
200141511,20014151,10,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211023.0,20211029,20211029,EXP,,CA-TEVA-2021-CA-1970822,TEVA,,76.0,YR,E,F,Y,,,20211029.0,,CN,CA,CA,2021,Q4,Elderly
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Haemoglobin increased,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Renal disorder,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Bacteraemia,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Moraxella infection,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Fatigue,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Lethargy,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Pyrexia,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Abdominal pain,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Cough,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Headache,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Liposarcoma,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,C-reactive protein increased,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Hydronephrosis,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Product dose omission issue,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200170791,20017079,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 milligram, Once a Day",,,N,,,,,300.0,MG,,QD,2021,Q4,Depressed mood,,2021,Q4,1,I,,20211021.0,20211030,20211030,EXP,,GB-AUROBINDO-AUR-APL-2021-044670,AUROBINDO,,33.0,YR,,M,Y,,,20211030.0,,HP,GB,GB,2021,Q4,Young Adult
200198912,20019891,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,,,,,,,,,,2021,Q4,Spondylolisthesis,,2021,Q4,2,F,,20211104.0,20211101,20211119,EXP,,JP-SUNOVION-2021DSP016145,SUNOVION,,56.0,YR,,M,Y,,,20211119.0,,CN,JP,JP,2021,Q4,Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Hydronephrosis,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Liposarcoma,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,C-reactive protein increased,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Fatigue,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Depressed mood,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Haemoglobin increased,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Bacteraemia,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Product dose omission issue,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Condition aggravated,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Lethargy,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Headache,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Pyrexia,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Cough,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Abdominal pain,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Renal disorder,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200235122,20023512,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 mg, QD",,,,,,,,300.0,MG,,,2021,Q4,Moraxella infection,,2021,Q4,2,F,,20211022.0,20211102,20211214,EXP,,GB-MICRO LABS LIMITED-ML2021-02874,MICRO LABS,,33.0,YR,,M,Y,,,20211215.0,,CN,GB,GB,2021,Q4,Young Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Psychogenic seizure,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Asthenia,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Eye disorder,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Pain,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Tic,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Anxiety,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Mobility decreased,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Drug ineffective,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Hypoaesthesia,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200595732,20059573,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,100.0,MG,Unknown,QD,2021,Q4,Neuralgia,,2021,Q4,2,F,,20211208.0,20211111,20211216,EXP,,CA-JNJFOC-20210905753,JOHNSON AND JOHNSON,,41.0,YR,A,M,Y,,,20211216.0,,CN,CA,CA,2021,Q4,Adult
200678432,20067843,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,100.0,MG,Tablet,,2021,Q4,Neutropenia,,2021,Q4,2,F,20211102.0,20211215.0,20211115,20211220,EXP,,JP-ASTELLAS-2021JP021823,ASTELLAS,,76.0,YR,,M,Y,,,20211220.0,,CN,JP,JP,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Stevens-Johnson syndrome,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,SJS-TEN overlap,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Dysphagia,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Lip oedema,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Oral candidiasis,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Skin lesion,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Toxic epidermal necrolysis,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Rash macular,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Blister,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200704665,20070466,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Ulcerative keratitis,,2021,Q4,5,F,,20211220.0,20211115,20211222,EXP,,NVSC2021PT256250,NOVARTIS,"Gama L, Duarte J, Santos e Silva A. Stevens-Johnson Syndrome-the cessation of therapy as the key to the cure. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211222.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,SJS-TEN overlap,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Macule,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Lip oedema,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Odynophagia,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Oral candidiasis,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Cholestasis,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Stevens-Johnson syndrome,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Toxic epidermal necrolysis,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Rash macular,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Visual impairment,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Ocular hyperaemia,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Ulcerative keratitis,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Pyrexia,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Dysphagia,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200732884,20073288,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,UNK,,,,,,,2021,Q4,Blister,,2021,Q4,4,F,,20211213.0,20211116,20211216,EXP,,NVSC2021PT260907,NOVARTIS,"Gama L, Duarte J, E Silva AS, Lopes JG, Rita H. Sindrome de Stevens-Johnson-o cessar da terapeutica como a chave da cura [Sindrome Stevens-Johnson-the cessation of therapy as the key to cure]. PORTUGUESE JOURNAL OF INTERNAL MEDICINE. 2021;28:623-4",79.0,YR,,F,Y,,,20211216.0,,HP,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Toxic epidermal necrolysis,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Acute kidney injury,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Stevens-Johnson syndrome,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Dysphagia,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Lip oedema,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,SJS-TEN overlap,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Ulcerative keratitis,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Oral candidiasis,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Rash macular,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200743423,20074342,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,U,,,,,,,,,2021,Q4,Blister,,2021,Q4,3,F,,20211122.0,20211116,20211206,EXP,,PT-PFIZER INC-202101531311,PFIZER,"Gama, L.. Stevens-Johnson Syndrome - the cessation of therapy as the key to the cure. Portuguese Journal of Internal Medicine. 2021;28:623-624",79.0,YR,,F,Y,,,20211206.0,,MD,PT,PT,2021,Q4,Elderly
200839471,20083947,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211115.0,20211118,20211118,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211118.0,,MD,CA,CA,2021,Q4,Elderly
200839471,20083947,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211115.0,20211118,20211118,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211118.0,,MD,CA,CA,2021,Q4,Elderly
200839471,20083947,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211115.0,20211118,20211118,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211118.0,,MD,CA,CA,2021,Q4,Elderly
200839471,20083947,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211115.0,20211118,20211118,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211118.0,,MD,CA,CA,2021,Q4,Elderly
200839471,20083947,20,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211115.0,20211118,20211118,EXP,,CA-BAUSCH-BL-2021-037764,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211118.0,,MD,CA,CA,2021,Q4,Elderly
200877141,20087714,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2021,Q4,Hypophagia,,2021,Q4,1,I,20210501.0,20211108.0,20211118,20211118,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110011567,ELI LILLY AND CO,,61.0,YR,,F,Y,75.0,KG,20211118.0,,CN,CN,CN,2021,Q4,Adult
200877141,20087714,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2021,Q4,Blood glucose increased,,2021,Q4,1,I,20210501.0,20211108.0,20211118,20211118,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110011567,ELI LILLY AND CO,,61.0,YR,,F,Y,75.0,KG,20211118.0,,CN,CN,CN,2021,Q4,Adult
200877141,20087714,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2021,Q4,Fungal infection,,2021,Q4,1,I,20210501.0,20211108.0,20211118,20211118,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110011567,ELI LILLY AND CO,,61.0,YR,,F,Y,75.0,KG,20211118.0,,CN,CN,CN,2021,Q4,Adult
200877141,20087714,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2021,Q4,Oliguria,,2021,Q4,1,I,20210501.0,20211108.0,20211118,20211118,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110011567,ELI LILLY AND CO,,61.0,YR,,F,Y,75.0,KG,20211118.0,,CN,CN,CN,2021,Q4,Adult
200877141,20087714,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, unknown",,,Y,,,,,,,,,2021,Q4,Weight increased,,2021,Q4,1,I,20210501.0,20211108.0,20211118,20211118,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202110011567,ELI LILLY AND CO,,61.0,YR,,F,Y,75.0,KG,20211118.0,,CN,CN,CN,2021,Q4,Adult
200907552,20090755,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,2,F,,20211129.0,20211119,20211203,EXP,,CA-BAUSCH-BL-2021-037776,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
200907552,20090755,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Asthma,,2021,Q4,2,F,,20211129.0,20211119,20211203,EXP,,CA-BAUSCH-BL-2021-037776,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
200907552,20090755,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,2,F,,20211129.0,20211119,20211203,EXP,,CA-BAUSCH-BL-2021-037776,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
200907552,20090755,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,,20211129.0,20211119,20211203,EXP,,CA-BAUSCH-BL-2021-037776,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
200907552,20090755,7,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,2,F,,20211129.0,20211119,20211203,EXP,,CA-BAUSCH-BL-2021-037776,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201037841,20103784,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK, qd (take one daily)",,,,,,,,,,,QD,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211123,20211123,EXP,GB-MHRA-TPP14880533C8938941YC1637089188592,GB-MYLANLABS-2021M1085609,MYLAN,,79.0,YR,,M,Y,82.0,KG,20211123.0,,MD,GB,GB,2021,Q4,Elderly
201097451,20109745,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,dose not provided,,,,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211124,20211124,EXP,GB-MHRA-TPP14880533C8938941YC1637089188592,GB-Eisai Medical Research-EC-2021-103407,EISAI,,79.0,YR,E,M,Y,82.0,KG,20211124.0,,MD,GB,GB,2021,Q4,Elderly
201100831,20110083,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"UNK UNK, unknown",,,,,,,,,,,,2021,Q4,Diabetes mellitus inadequate control,,2021,Q4,1,I,,20211116.0,20211124,20211124,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202111009068,ELI LILLY AND CO,,57.0,YR,,M,Y,75.0,KG,20211124.0,,CN,CN,CN,2021,Q4,Adult
201137751,20113775,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,take one daily,,,U,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211125,20211125,EXP,GB-MHRA-TPP14880533C8938941YC1637089188592,GB-TORRENT-00026848,TORRENT,,79.0,YR,E,M,Y,82.0,KG,20211125.0,,MD,GB,GB,2021,Q4,Elderly
201169151,20116915,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,take one daily,,,,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211126,20211126,EXP,GB-MHRA-ADR 26210804,GB-Accord-245775,ACCORD,,79.0,YR,,M,Y,82.0,KG,20211126.0,,MD,GB,GB,2021,Q4,Elderly
201178941,20117894,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,take one daily,,,,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211126,20211126,EXP,GB-MHRA-ADR 26210804,GB-CPL-002650,CADILA,,79.0,YR,,M,Y,82.0,KG,20211126.0,,MD,GB,GB,2021,Q4,Elderly
201228421,20122842,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,take one daily,,,U,,,,,,,,,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211129,20211129,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-318927,RANBAXY,,79.0,YR,,M,Y,82.0,KG,20211129.0,,MD,GB,GB,2021,Q4,Elderly
201264161,20126416,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981839,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
201264161,20126416,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981839,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
201264161,20126416,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981839,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
201264161,20126416,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981839,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
201264161,20126416,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981839,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,CN,CA,CA,2021,Q4,Elderly
201265681,20126568,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981818,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,MD,CA,CA,2021,Q4,Elderly
201265681,20126568,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981818,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,MD,CA,CA,2021,Q4,Elderly
201265681,20126568,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981818,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,MD,CA,CA,2021,Q4,Elderly
201265681,20126568,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981818,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,MD,CA,CA,2021,Q4,Elderly
201265681,20126568,21,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211122.0,20211129,20211129,EXP,,CA-TEVA-2021-CA-1981818,TEVA,,76.0,YR,E,F,Y,,,20211129.0,,MD,CA,CA,2021,Q4,Elderly
201329191,20132919,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1 dosage form, Once a Day(take one daily)",,,U,,,,,,,,QD,2021,Q4,Acute myocardial infarction,,2021,Q4,1,I,20211116.0,20211117.0,20211201,20211201,EXP,,GB-AUROBINDO-AUR-APL-2021-048546,AUROBINDO,,79.0,YR,,M,Y,82.0,KG,20211201.0,,MD,GB,GB,2021,Q4,Elderly
201469271,20146927,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211125.0,20211203,20211203,EXP,,CA-TEVA-2021-CA-1983159,TEVA,,76.0,YR,E,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201469271,20146927,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211125.0,20211203,20211203,EXP,,CA-TEVA-2021-CA-1983159,TEVA,,76.0,YR,E,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201469271,20146927,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211125.0,20211203,20211203,EXP,,CA-TEVA-2021-CA-1983159,TEVA,,76.0,YR,E,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201469271,20146927,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211125.0,20211203,20211203,EXP,,CA-TEVA-2021-CA-1983159,TEVA,,76.0,YR,E,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201469271,20146927,17,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211125.0,20211203,20211203,EXP,,CA-TEVA-2021-CA-1983159,TEVA,,76.0,YR,E,F,Y,,,20211203.0,,MD,CA,CA,2021,Q4,Elderly
201502451,20150245,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 milligram, qd",,,,,,,,300.0,MG,,,2021,Q4,Lupus-like syndrome,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,US-AVET LIFESCIENCES LTD-2021-AVET-000067,EMCURE,"Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P. Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use. Cureus. 2021;13(10):e18974",59.0,YR,,M,Y,,,20211206.0,,HP,US,US,2021,Q4,Adult
201502451,20150245,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 milligram, qd",,,,,,,,300.0,MG,,,2021,Q4,Anti-neutrophil cytoplasmic antibody positive vasculitis,,2021,Q4,1,I,,20211130.0,20211206,20211206,EXP,,US-AVET LIFESCIENCES LTD-2021-AVET-000067,EMCURE,"Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P. Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10 Years of Hydralazine Use. Cureus. 2021;13(10):e18974",59.0,YR,,M,Y,,,20211206.0,,HP,US,US,2021,Q4,Adult
201520291,20152029,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg daily,,,D,,,,,300.0,MG,,,2021,Q4,Pulmonary haemorrhage,,2021,Q4,1,I,,20211128.0,20211206,20211206,EXP,,US-Navinta LLC-000208,NAVINTA LLC,US-Navinta LLC-000208-01_Initial Source Document,59.0,YR,A,M,Y,,,20211206.0,,HP,US,,2021,Q4,Adult
201520291,20152029,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg daily,,,D,,,,,300.0,MG,,,2021,Q4,Anti-neutrophil cytoplasmic antibody positive vasculitis,,2021,Q4,1,I,,20211128.0,20211206,20211206,EXP,,US-Navinta LLC-000208,NAVINTA LLC,US-Navinta LLC-000208-01_Initial Source Document,59.0,YR,A,M,Y,,,20211206.0,,HP,US,,2021,Q4,Adult
201520291,20152029,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 mg daily,,,D,,,,,300.0,MG,,,2021,Q4,Retroperitoneal haemorrhage,,2021,Q4,1,I,,20211128.0,20211206,20211206,EXP,,US-Navinta LLC-000208,NAVINTA LLC,US-Navinta LLC-000208-01_Initial Source Document,59.0,YR,A,M,Y,,,20211206.0,,HP,US,,2021,Q4,Adult
201545321,20154532,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,,,,204042.0,100.0,MG,Tablet,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211130.0,20211202.0,20211207,20211207,EXP,GB-MHRA-EYC 00267877,GB-JNJFOC-20211207610,JOHNSON AND JOHNSON,,74.0,YR,E,M,Y,,,20211207.0,,PH,GB,GB,2021,Q4,Elderly
201650691,20165069,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,300.0,MG,,,2021,Q4,Anti-neutrophil cytoplasmic antibody positive vasculitis,,2021,Q4,1,I,,20211128.0,20211209,20211209,EXP,,US-CPL-002668,CADILA,"Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P. Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10?Years of Hydralazine Use. Cureus. 2021 Oct 22;13(10):e18974",59.0,YR,,M,Y,,,20211209.0,,HP,US,US,2021,Q4,Adult
201650691,20165069,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,300.0,MG,,,2021,Q4,Glomerulonephritis rapidly progressive,,2021,Q4,1,I,,20211128.0,20211209,20211209,EXP,,US-CPL-002668,CADILA,"Russe-Russe JR, Pellegrini JR Jr, Alvarez-Betancourt A, Munshi RF, Anand P. Fulminant Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis After 10?Years of Hydralazine Use. Cureus. 2021 Oct 22;13(10):e18974",59.0,YR,,M,Y,,,20211209.0,,HP,US,US,2021,Q4,Adult
201743722,20174372,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,2,F,,20211227.0,20211213,20211230,EXP,,CA-BAUSCH-BL-2021-040780,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211230.0,,MD,CA,CA,2021,Q4,Elderly
201743722,20174372,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,2,F,,20211227.0,20211213,20211230,EXP,,CA-BAUSCH-BL-2021-040780,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211230.0,,MD,CA,CA,2021,Q4,Elderly
201743722,20174372,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,2,F,,20211227.0,20211213,20211230,EXP,,CA-BAUSCH-BL-2021-040780,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211230.0,,MD,CA,CA,2021,Q4,Elderly
201743722,20174372,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,2,F,,20211227.0,20211213,20211230,EXP,,CA-BAUSCH-BL-2021-040780,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211230.0,,MD,CA,CA,2021,Q4,Elderly
201743722,20174372,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,2,F,,20211227.0,20211213,20211230,EXP,,CA-BAUSCH-BL-2021-040780,BAUSCH AND LOMB,,76.0,YR,,F,Y,,,20211230.0,,MD,CA,CA,2021,Q4,Elderly
201786661,20178666,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,20211110.0,20211208.0,20211214,20211214,EXP,LU-ALMPS-202103181,LU-JNJFOC-20211222894,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,92.0,KG,20211214.0,,PH,LU,LU,2021,Q4,Adult
201786661,20178666,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2021,Q4,Diabetic ketoacidosis,,2021,Q4,1,I,20211110.0,20211208.0,20211214,20211214,EXP,LU-ALMPS-202103181,LU-JNJFOC-20211222894,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,92.0,KG,20211214.0,,PH,LU,LU,2021,Q4,Adult
201786661,20178666,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2021,Q4,Vomiting,,2021,Q4,1,I,20211110.0,20211208.0,20211214,20211214,EXP,LU-ALMPS-202103181,LU-JNJFOC-20211222894,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,92.0,KG,20211214.0,,PH,LU,LU,2021,Q4,Adult
201786661,20178666,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2021,Q4,Nausea,,2021,Q4,1,I,20211110.0,20211208.0,20211214,20211214,EXP,LU-ALMPS-202103181,LU-JNJFOC-20211222894,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,92.0,KG,20211214.0,,PH,LU,LU,2021,Q4,Adult
201786661,20178666,1,PS,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,Oral,,,,Y,,,,204353.0,,,Tablet,,2021,Q4,Abdominal pain,,2021,Q4,1,I,20211110.0,20211208.0,20211214,20211214,EXP,LU-ALMPS-202103181,LU-JNJFOC-20211222894,JOHNSON AND JOHNSON,,56.0,YR,A,M,Y,92.0,KG,20211214.0,,PH,LU,LU,2021,Q4,Adult
201968822,20196882,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,204042.0,,,Tablet,,2021,Q4,Stevens-Johnson syndrome,,2021,Q4,2,F,,20211215.0,20211217,20211220,EXP,,PT-JNJFOC-20211130496,JOHNSON AND JOHNSON,,79.0,YR,E,F,Y,,,20211221.0,,HP,PT,PT,2021,Q4,Elderly
202089421,20208942,9,C,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,CANAGLIFLOZIN\METFORMIN HYDROCHLORIDE,1,,,,,,,,,,,,,,2021,Q4,Rheumatoid arthritis,,2021,Q4,1,I,20211206.0,20211217.0,20211220,20211220,EXP,,US-GILEAD-2021-0562130,GILEAD,,69.0,YR,E,F,Y,,,20211220.0,,CN,US,US,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Nasopharyngitis,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Off label use,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Blood pressure diastolic decreased,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Urinary tract infection,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Contusion,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Vascular stenosis,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Blood pressure fluctuation,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Rheumatoid arthritis,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Heart rate increased,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Hypertension,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Pain,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Intercepted medication error,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Fall,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Drug ineffective,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Arthralgia,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Cystitis,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Kidney infection,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Nodule,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Hypothyroidism,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Blood pressure diastolic abnormal,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Blood pressure increased,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Hypotension,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Breast disorder,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Weight decreased,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Finger deformity,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Steroid diabetes,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Oxygen saturation decreased,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Lower respiratory tract infection,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202158682,20215868,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2021,Q4,Fibromyalgia,,2021,Q4,2,F,,20211216.0,20211222,20211231,EXP,,CA-ROCHE-2982851,ROCHE,,67.0,YR,,F,Y,,,20211231.0,,HP,CA,,2021,Q4,Elderly
202322441,20232244,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,Dosage is uncertain.,,,,,,,,,,XXX,,2021,Q4,Off label use,,2021,Q4,1,I,20200730.0,20201013.0,20211227,20211227,EXP,,JP-ROCHE-2982919,ROCHE,,55.0,YR,,M,Y,93.0,KG,20211227.0,,PH,JP,JP,2021,Q4,Adult
202322441,20232244,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,Dosage is uncertain.,,,,,,,,,,XXX,,2021,Q4,Hypertriglyceridaemia,,2021,Q4,1,I,20200730.0,20201013.0,20211227,20211227,EXP,,JP-ROCHE-2982919,ROCHE,,55.0,YR,,M,Y,93.0,KG,20211227.0,,PH,JP,JP,2021,Q4,Adult
202322441,20232244,6,C,CANAGLIFLOZIN\TENELIGLIPTIN,CANAGLIFLOZIN\TENELIGLIPTIN,1,Unknown,Dosage is uncertain.,,,,,,,,,,XXX,,2021,Q4,Blood triglycerides increased,,2021,Q4,1,I,20200730.0,20201013.0,20211227,20211227,EXP,,JP-ROCHE-2982919,ROCHE,,55.0,YR,,M,Y,93.0,KG,20211227.0,,PH,JP,JP,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Hypoacusis,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Depression,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202356401,20235640,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,Tablet,,2021,Q4,Wheezing,,2021,Q4,1,I,,20211216.0,20211228,20211228,EXP,,CA-AUROBINDO-AUR-APL-2021-052727,AUROBINDO,,51.0,YR,,F,Y,,,20211228.0,,HP,CA,CA,2021,Q4,Adult
202375641,20237564,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-TEVA-2021-CA-1993233,TEVA,,76.0,YR,E,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Elderly
202375641,20237564,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-TEVA-2021-CA-1993233,TEVA,,76.0,YR,E,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Elderly
202375641,20237564,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-TEVA-2021-CA-1993233,TEVA,,76.0,YR,E,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Elderly
202375641,20237564,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-TEVA-2021-CA-1993233,TEVA,,76.0,YR,E,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Elderly
202375641,20237564,15,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-TEVA-2021-CA-1993233,TEVA,,76.0,YR,E,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Elderly
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Hypoacusis,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Depression,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Wheezing,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202392551,20239255,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,Unknown,,,,,Tablet,,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211221.0,20211228,20211228,EXP,,"CA-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-145300",BOEHRINGER INGELHEIM,,51.0,YR,A,F,Y,,,20211228.0,,MD,CA,CA,2021,Q4,Adult
202403341,20240334,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Off label use,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20211228.0,,HP,CA,CA,2021,Q4,Adult
202403341,20240334,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Tooth fracture,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20211228.0,,HP,CA,CA,2021,Q4,Adult
202403341,20240334,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Alopecia,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20211228.0,,HP,CA,CA,2021,Q4,Adult
202403341,20240334,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Condition aggravated,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20211228.0,,HP,CA,CA,2021,Q4,Adult
202403341,20240334,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,Unknown,,,,,,,,,,,,2021,Q4,Pulpitis dental,,2021,Q4,1,I,,20211220.0,20211228,20211228,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-30067,SAMSUNG BIOEPIS,,61.0,YR,A,F,Y,91.0,KG,20211228.0,,HP,CA,CA,2021,Q4,Adult
202478671,20247867,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211221.0,20211229,20211229,EXP,,CA-TAKEDA-2021TUS081659,TAKEDA,,76.0,YR,,F,Y,,,20211229.0,,HP,CA,CA,2021,Q4,Elderly
202478671,20247867,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211221.0,20211229,20211229,EXP,,CA-TAKEDA-2021TUS081659,TAKEDA,,76.0,YR,,F,Y,,,20211229.0,,HP,CA,CA,2021,Q4,Elderly
202478671,20247867,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211221.0,20211229,20211229,EXP,,CA-TAKEDA-2021TUS081659,TAKEDA,,76.0,YR,,F,Y,,,20211229.0,,HP,CA,CA,2021,Q4,Elderly
202478671,20247867,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211221.0,20211229,20211229,EXP,,CA-TAKEDA-2021TUS081659,TAKEDA,,76.0,YR,,F,Y,,,20211229.0,,HP,CA,CA,2021,Q4,Elderly
202478671,20247867,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211221.0,20211229,20211229,EXP,,CA-TAKEDA-2021TUS081659,TAKEDA,,76.0,YR,,F,Y,,,20211229.0,,HP,CA,CA,2021,Q4,Elderly
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Dyspnoea,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Wheezing,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Asthma,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Depression,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Sleep disorder due to a general medical condition,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Loss of personal independence in daily activities,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Hypoacusis,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202669071,20266907,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,Tablet,,2021,Q4,Diabetes mellitus,,2021,Q4,1,I,,20211227.0,20211231,20211231,EXP,,CA-BAUSCH-BL-2021-042654,BAUSCH AND LOMB,,51.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Adult
202670491,20267049,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Hyperglycaemia,,2021,Q4,1,I,,20211221.0,20211231,20211231,EXP,,CA-PFIZER INC-202101877404,PFIZER,,76.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Elderly
202670491,20267049,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Gastrooesophageal reflux disease,,2021,Q4,1,I,,20211221.0,20211231,20211231,EXP,,CA-PFIZER INC-202101877404,PFIZER,,76.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Elderly
202670491,20267049,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Full blood count abnormal,,2021,Q4,1,I,,20211221.0,20211231,20211231,EXP,,CA-PFIZER INC-202101877404,PFIZER,,76.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Elderly
202670491,20267049,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Type 2 diabetes mellitus,,2021,Q4,1,I,,20211221.0,20211231,20211231,EXP,,CA-PFIZER INC-202101877404,PFIZER,,76.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Elderly
202670491,20267049,11,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2021,Q4,Asthma,,2021,Q4,1,I,,20211221.0,20211231,20211231,EXP,,CA-PFIZER INC-202101877404,PFIZER,,76.0,YR,,F,Y,,,20211231.0,,CN,CA,CA,2021,Q4,Elderly
